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ABSTRACT
Torok, Zoltan A. Effects of Two Types of Creatine Feeding and Doxorubicin on Skeletal
Muscle Apoptotic Markers. Published Doctor of Philosophy Dissertation,
University of Northern Colorado, 2019.
Doxorubicin (Dox) is a widely used anthracycline antibiotic used to treat a
number of hematological and solid tumor cancers. Dosage however, is limited due to its
toxic effects in healthy tissues. Negative consequences include myotoxicity in skeletal
muscle, which may limit mobility and activities of daily living. Doxorubicin increases the
formation of reactive oxygen species, which triggers apoptosis in the tumor and healthy
tissue. Skeletal muscle undergoes apoptosis in response to Dox treatment, via the
activation of the cleaved caspase-3 and its downstream target, poly(ADP-ribose)
polymerase. Creatine monohydrate (Cr), a naturally occurring chemical, when taken
exogenously, can improve athletic performance. Recently, it has been shown that Cr can
positively impact several diseases and act as a antioxidant, capable of scavenging free
radicals and reducing apoptosis. Purpose: To determine the effect of two types of Cr
feeding and Dox administration on skeletal muscle apoptotic proteins at two separate
time points. Methods: Ten week old male Sprague-Dawley rats were randomly assigned
to one of six groups: control + saline (Con-Sal, n=10), control + doxorubicin (Con-Dox,
n=10), creatine 1 + saline (C1-Sal, n=10), creatine 1 + doxorubicin (C1-Dox, n=10),
creatine 2 + saline (C2-Sal, n=10), creatine 2 + doxorubicin (C2-Dox, n=10). Animals
were fed for four weeks and were injected with a bolus 15 mg/kg i.p. injection of Dox or
Sal and sacrificed either 1-day or 3-days post injection. Post injection, the extensor
digitorum longus (EDL), soleus (SOL), and diaphragm (DIA) were excised and Western
blotting for expression of cleaved PARP, caspase-3, and cleaved caspase-3 was

conducted. Creatine concentration was also analyzed using a commercially available
assay kit. Results: A main drug effect was observed, with increased levels of apoptosis
observed in the 1-day EDL, SOL, and in the 3-day EDL. Equally, a main drug effect was
observed, with decreased caspase-3 levels in the 3-day SOL, and cleaved PARP levels in
the 3-day DIA. There was a diet effect, with increased cleaved PARP levels in the 1-day
EDL, SOL, and cleaved caspase-3 levels in the 3-day EDL. An equal diet effect was
detected, with decreased caspase-3 levels in the 1-day EDL and cleaved caspase-3 levels
in the 1-day SOL and DIA. The 1-day SOL had lower creatine concentration with Dox
administration and the 3-day EDL had decreased Cr concentrations with both Dox
administration and Cr feeding. Conclusion: Doxorubicin had the largest impact on
apoptosis in the EDL, suggesting Dox’s effects on apoptosis may differ between tissue.
Creatine concentration in the EDL was lower in animals receiving Dox, and this was not
observed in the DIA, supporting the idea that Dox toxicity may differ between tissue.
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CHAPTER I
INTRODUCTION TO THE STUDY
Background
Cancer is a group of diseases characterized by the uncontrolled growth and spread
of abnormal cells. If this abnormal growth is left uncontrolled, it can result in death.
According to Siegel, Miller, and Jemal (2019), as of January 1, 2016, more than 15.5
million Americans have a history of cancer. About 1.7 million new cancer cases are
expected to be diagnosed in 2018, with about 609,640 Americans dying from the disease
(Siegel et al., 2019). The overall age-adjusted cancer death rate has improved, decreasing
from 215 deaths per 100,000 in 1991 to 159 deaths per 100,000 in 2015 which is a 26%
decrease (Siegel et al., 2019). The improvement in age-adjusted death is largely due to
advanced screening, increased awareness, and improved treatments (Siegel et al., 2019).
Improvement in age-adjusted deaths should be interpreted with caution as they do not
always indicate progress against cancer. In fact, cancer is still one of the leading causes
of death and disease in the US, costing Americans $80.2 billion dollars in 2015 (Siegel et
al., 2019).
Currently, there are three types of cancer treatment options available: surgery,
radiation, and pharmacological therapy. These treatments can be used alone or in most
cases, in combination. Surgery is the removal of a tumor and can be used to diagnose
cancer, determine how far it has spread, stop growth and ultimately, the primary method
to “cure” the patient. Radiation is the use of high energy waves/particles to destroy or
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severely damage a tumor. Pharmacological therapy is the use of medication to destroy or
slow growth of a tumor. Medications can include chemotherapy, targeted therapy,
immunotherapy, hormone therapy, and other supportive medications.
Pharmacological therapy, specifically chemotherapy, is often used as part of a
patient’s cancer treatment. Doxorubicin (Dox), or Adriamycin, is an anthracycline
antibiotic chemotherapy drug synthesized from the soil fungus Streptomyces.
Doxorubicin is commonly used to treat a variety of cancers including breast, ovarian,
bladder, lung, thyroid, and stomach cancers. Doxorubicin dosing is dependent on a
patient’s height, weight, general health, type of cancer, and has a lifetime maximal dose.
A lifetime maximal dose means a patient can only receive a set amount of Dox in their
lifetime and exceeding that dose can result in death from causes other than cancer.
Doxorubicin is typically administered via intravenous injection (although in some
cancers, such as peritoneal tumors, an intraperitoneal injection is used) and exerts its anticancer effects by halting the cell cycle in the tumor, preventing division. Doxorubicin
halts the cell cycle by three main mechanisms, (1) intercalation into DNA disrupting
replication, (2) disruption of topoisomerase-II-mediated DNA repair, and (3) generation
of free radicals, which damages cellular membranes, DNA and proteins (Thorn et al.,
2011). Along with its tumor damaging capabilities, Dox has the capacity to damage
health tissue, specifically (to the research conducted in our lab), cardiac tissue and
skeletal muscle.
Doxorubicin administration may result in chronic cardiotoxicity, with an
estimated incidence of about 1.7% (Von Hoff et al., 1979) and is usually evident within
30 days of administration. Doxorubicin cardiotoxicity is a result of increased oxidative
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stress (increased levels of reactive oxygen species and lipid peroxidation) (Takemura &
Fujiwara, 2007), decreased levels of antioxidants and sulfhydryl groups (Singal, Li,
Kumar, Danelisen, & Illiskovic, 2000), inhibition of nucleic acid and protein synthesis,
release of vasoactive amines (Bristow et al., 1980), altered adrenergic function, and
decreased expression of cardiac-specific genes (Tong, Ganguly, & Singal, 1991).
In skeletal muscle, Dox treatment decreased maximal twitch force in the extensor
digitorum longus and soleus, as well as, increased fatigue in the soleus (Gilliam et al.,
2012; Hydock, Lien, Jensen, Schneider, & Hayward, 2011; van Norren et al., 2009).
Equally, intraperitoneal injections of Dox decreased fiber bundle diameter and absolute
force production in the murine diaphragm (Bonifati et al., 2000). Further, rodents
injected with Dox showed loss of myofibrillar organization with interstitial edema
(Doroshow, Tallent, & Schechter, 1985), nucleolar segregation, and altered distribution
of the perinucleolar chromatin in hindlimb skeletal muscle (Merski, Daskal, & Busch,
1978). The increased skeletal muscle fatigue and loss of skeletal muscle size described
above resulted from increased apoptotic activation (Hilder, Carlson, Haystead, Krebs, &
Graves, 2005), mediated through increased Dox-induced ROS formation (Timolati et al.,
2006) and activation of caspases (Wang et al., 2004).
Currently there is a push to uncover nutraceutical interventions that can mitigate
Dox-induced myotoxicity. Studies have shown that exercise mitigates Dox-induced
myotoxcity through the impedance of the Dox-induced ROS production and protease
activation (Smuder, Kavazis, Min, & Powers, 1985), preservation of maximal twitch
force, attenuation of skeletal muscle fatigue (Bredahl, Pfannenstiel, Quinn, Hayward, &
Hydock, 2016) and reduction in chemotherapy-induced muscle fatigue (Fairman, Hyde,
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& Focht, 2016; Van Moll, Schep, Vreugdenhil, Savelberg, & Husson, 2016). However,
exercise as an intervention is problematic because adherence significantly decreases in
patients that are in treatment and in those who have just finished treatment (Courneya et
al., 2007; Markes, Brockow, & Resch, 2006; McNeely et al., 2006; Mutrie et al., 2007).
Equally, research has shown that exercise preconditioning is protective against Doxinduced weakness and fatigue (Kavazis, Smuder, & Powers, 1985; Smuder et al., 1985)
however, it has been reported that 30-40% of newly diagnosed cancer patients meet the
minimum recommendations for physical activity, which makes this intervention not a
viable option. This leads to a further search for a nutraceutical intervention that can
mitigate Dox-induced myotoxicity and have a high rate of adherence in patients whom
exercise adherence is typically low. Supplementing the diet with creatine as a
nutraceutical intervention to mitigate Dox-induced myotoxicity is a possibility.
Creatine monohydrate (Cr) is perhaps one of the most widely used nutraceuticals
ingested in an attempt to improve athletic performance. A large amount of research has
been done on Cr supplementation, in efforts to delineate its sport-specific effects. It is
hypothesized that Cr acts through a number of pathways and appears to be most effective
in short-term, high-intensity physical activities. However, the past decade has showed
that the use of Cr for therapeutic purposes has received increasing attention (Gualano,
Artioli, Poortmans, & Lancha Junior, 2009). Creatine supplementation is beneficial in a
large number of muscular, neurological, and cardiovascular diseases (Bender et al., 2007;
Felber et al., 2000; Gordon et al., 1995; Holtzman et al., 1999; Matthews et al., 1999;
Mazzini et al., 2001; Neubauer et al., 1999; Sharov et al., 1987; Stout, Eckerson, May,
Coulter, & Bradley-Popovich, 2001; Tarnopolsky et al., 2004; Tarnopolsky, 2007;
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Vorgerd et al., 2000; Wyss & Schulze, 2002;); however, less documented are the effects
of Cr on Dox-induced skeletal muscle dysfunction, and there is a lack of research on
possible mechanisms leading to improvements in Dox-induced skeletal muscle
dysfunction.
To the author’s knowledge, Bredahl and Hydock (2017) published the only study
to examine the effects of Cr on Dox-induced skeletal muscle dysfunction. In this ex vivo
study, Bredahl and Hydock (2017) found that incubating the soleus and extensor
digitorum longus in creatine monohydrate prior to Dox treatment attenuated Dox-induced
fatigue in both the soleus and the extensor digitorum longus. Although mechanisms
contributing to the results were not analyzed in the aforementioned study, it is postulated
that Cr acted as an antioxidant, decreasing ROS formation (Lawler & Powers, 1998;
Sestili et al., 2006; Sestili et al., 2009), and preserving muscle function. In light of the
above findings, and given that Dox treatment increases apoptosis, it was imperative to
examine what effect Cr supplementation had on the apoptosis in Dox treated animals,
specifically the apoptotic markers cleaved poly ADP ribose polymerase (PARP) and
cleaved caspase-3, in skeletal muscle from Dox treated animals. It is important to begin
to elucidate the benefits Cr supplementation has on Dox-induced skeletal muscle toxicity.
Statement of Purpose
The purpose of the current study was to examine the effects doxorubicin and two
types of creatine monohydrate feeding, had on cleaved (PARP), caspase-3, and cleaved
caspase-3, at 1-day post injection and 3-days post injection, in the extensor digitorum
longus (EDL), soleus (SOL), and diaphragm (DIA).
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Research Hypotheses
H1

Dox alone will increase apoptosis in the SOL, EDL, and DIA.

H2

Both types of Cr supplemented diets alone will have no effect on,
apoptosis,at either 1-day or 3-day post-injection time points.

H3

Cr will attenuate Dox-induced apoptosis, with a higher percent Cr feeding
having a greater attenuation than a lower percent Cr feeding in the SOL,
EDL, and DIA.

H4

Dox alone will increase apoptosis more at the 3-days post injection time
point, than at 1-day post injection time point in the SOL, EDL, and DIA.

H5

The 4% Cr supplemented diet will have a greater impact on attenuating
Dox-induced increases in apoptosis, than the 2% Cr supplemented diet, at
the 3-days post injection time point in the SOL, EDL, and DIA.

H6

Both types of Cr feeding will attenuate Dox-induced increases in apoptosis
to a greater extent in the EDL, than to either the SOL or DIA at both the 1day and 3-days post injection time points.

H7

Free Cr and phosphocreatine levels will be greater in the 4% Cr
supplemented diet, than the 2% Cr supplemented diet, in the SOL, EDL,
and DIA, at both 1-day and 3-days post injection time points.
Need for Study

It is well documented that chemotherapy treatment increases muscle fatigue and
weakness leading to decreases in activities of daily living (ADL). Specifically, patients
treated with Dox exhibit disrupted skeletal muscle function resulting in debilitating
muscle weakness (Gilliam et al., 2012). Any treatment or intervention that can reduce or
mitigate chemotherapy-induced muscle fatigue and weakness will improve a patients
ADL, and overall quality of life. Animal studies have shown that exercise can mitigate
chemotherapy-induced muscle fatigue, weakness, and cardiovascular dysfunction
(Fairman, et al., 2016; Van Moll et al., 2016); however, adherence to exercise programs
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during and post chemotherapy is very low, and a low percentage of cancer patients are
active upon entering a treatment program (Courneya et al., 2007; Markes et al., 2006;
McNeely et al., 2006; Mutrie et al., 2007). Therefore, it is important to find interventions
that improve chemotherapy-induced muscle fatigue, weakness, and ADL and have the
potential for greater adherence. Creatine supplementation has the potential to be such an
intervention. Creatine can be taken daily, either mixed in liquid or food, and is generally
well tolerated. Although not researched in human populations receiving chemotherapy,
in healthy populations, creatine supplementation has been shown to increase aerobic
performance and anaerobic capacity (Chwalbinska-Moneta, 2003). In light of these
findings, there was rationale for investigating what effect creatine may have on muscular
fatigue and weakness in patients receiving chemotherapy as a way of improving ADL’s
and attenuating Dox myotoxicity.
Preliminary Findings
Recent research was conducted on twenty rodents that were randomly assigned to
receive either a bolus 15 mg/kg Dox injection (Dox, n=10) or an equivalent sterile saline
injection (Con, n=10) and sacrificed 1-day post injection. Animals were anesthetized
with sodium pentobarbital (50 mg/kg). After the rodent was completely anesthetized (i.e.
no response with a tail pinch) the left soleus (SOL), left extensor digitorum longus (EDL)
and diaphragm (DIA) were removed, trimmed, weighed, flash frozen in liquid nitrogen,
and stored at -800C for biochemical analysis. The tissues were homogenized, and
Western blotting analysis was conducted on the SOL, EDL, and DIA for the presence of
cleaved PARP and caspase-3.
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One-day Extensor Digitorum Longus
Apoptotic Protein Levels
In the EDL (Figure 1), an unpaired t-test revealed no significant effects in cleaved
PARP levels, p>0.05 (Figure 1A). There was a significant drug effect, with the Dox
group exhibiting lower caspase-3 levels, p<0.05 (Figure 1B).
One-day Soleus Apoptotic
Protein Levels
In the SOL (Figure 2) no main effects were observed (p>0.05) for cleaved PARP
(Figure 2A) and caspase-3 (Figure 2B).
One-day Diaphragm Apoptotic
Protein Levels
In the DIA (Figure 3) no main effects were observed (p>0.05) for cleaved PARP
(Figure 3A) and caspase-3 (Figure 3B).

9

Figure 1.1-day EDL apoptotic protein levels, (A) cleaved PARP and (B) caspase-3.
EDL = extensor digitorum longus, kDa = kilodalton, OD = optical density, Con = control
saline, n=10; Dox = control doxorubicin, n=10; Values are mean ± SEM.
(B) significant drug effect (p<0.05)
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Figure 2. 1-day SOL apoptotic protein levels, (A) cleaved PARP and (B) caspase-3.
SOL = soleus, kDa = kilodalton, OD = optical density, Con = control saline, n=10; Dox =
control doxorubicin, n=10; Values are mean ± SEM.
No significant effects (p>0.05)
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Figure 3. 1-day DIA apoptotic protein levels, (A) cleaved PARP and (B) caspase-3.
DIA = diaphragm, kDa = kilodalton, OD = optical density, Con = control saline, n=10;
Dox = control doxorubicin, n=10; Values are mean ± SEM.
No significant effects (p>0.05)
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Discussion
Figure 1B showed that Dox treatment significantly affected caspase-3 levels in
the EDL. Equally, although not significant, Figure 1B shows a trend for higher cleaved
PARP levels with Dox administration. The changes in caspase-3 and cleaved PARP
levels suggest an increase in apoptosis in the EDL with Dox. In the SOL and DIA,
although not significant, there were increased levels of cleaved PARP with Dox
administration, once again, suggesting that apoptosis may be increased in the SOL and
DIA with Dox. These results suggest that in the EDL, SOL, and DIA, Dox
administration may increase apoptosis.
To further explore the effects of Dox treatment on apoptotic protein expression,
adding the protein cleaved caspase-3 to the study will be important to see if the decrease
in whole caspase-3 expression (observed DIA and EDL in the pilot study) is coupled with
an increase in cleaved caspase-3 expression. In light of these findings, further
exploration is warranted to examine what effect different doses of creatine monohydrate
may have on cleaved PARP, caspase-3, and cleaved caspase-3 in the SOL, EDL, and
DIA. Equally, adding an additional time point (3-days post injection) will broaden our
understanding of how Dox may impact apoptosis, via measuring the changes in cleaved
PARP, caspase-3, and cleaved caspase-3 levels. The data gathered will be useful in
beginning to illuminate what role creatine monohydrate may have in reducing Doxinduced myotoxicity.
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CHAPTER II
REVIEW OF THE LITERATURE
Doxorubicin
Doxorubicin (Dox) or Adriamycin, and sometimes Rubex, is an Anthracycline
antibiotic, synthesized from the soil fungus Streptomyces. Doxorubicin is among the
most commonly used drugs for treating a wide range of human cancers, including
leukemias, Wilms tumor, neuroblastoma, soft tissue and bone sarcomas, breast
carcinoma, ovarian carcinoma, transitional cell bladder carcinoma, thyroid carcinoma,
gastric carcinoma, Hodgkin’s disease, malignant lymphoma, and lung cancer.
Doxorubicin is administered via intravenous injection through a central line or peripheral
venous line over several minutes and is given in 21-day intervals (Johnson-Arbor &
Dubey, 2017). Doxorubicin dosing is calculated using body surface area derived from
the Du Bois and Du Bois formula published in 1916 (Pouliquen et al., 2011), and due to
its induction of cardiotoxicity and heart failure (Chatterjee, Zhang, Honbo, & Karliner,
2010), has a maximum lifetime dose not to exceed 450 mg/m2 (Rahman, Yusuf, & Ewer,
2007).
Although not completely elucidated, the proposed mechanisms that explain Dox’s
tumor killing activity are redox cycling in the mitochondria, topoisomerase inhibition,
oxidative stress, and apoptosis signaling (Wang et al., 2004). By far the most damaging
activity of Dox is its redox cycling, and will be furthered explained in the section,
‘Doxorubicin – Redox Cycling’.
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Reactive Oxygen Species
The utilization of molecular oxygen by mammals leads to the formation of
reactive oxygen species (ROS). Reactive oxygen species are small molecules that are
short-lived and highly reactive (Halliwell, 2011). ROS can be generated endogenously
during mitochondrial oxidative phosphorylation, or via interactions with exogenous
sources. The main ROS consist of hydrogen peroxide (H2O2), hydroxyl radical (HO•),
nitric oxide (NO•), peroxyl radical (ROO•), peroxynitrite anion (ONOO-), and
superoxide anion (O2•-) and consist of a radical and non-radical oxygen species formed
by the partial reduction of oxygen. Reactive oxygen species can be generated by both
exogenous and endogenous stimuli. Endogenous production occurs when electrons leak
during mitochondrial electron transport chain activity (Dickinson & Chang, 2011).
Superoxide is produced in complexes I and III of the electron transport chain, by NADPH
oxidases, and via enzymatic activation of cytochrome P450 reductases (Bae, Oh, Rhee, &
Yoo, 2011). The powerful oxidant peroxynitrite anion (ONOO-) is formed when the
superoxide anion (O2•-) reacts with the reactive nitrogen species (RNS) nitric oxide (NO•)
(Dickinson & Chang, 2011). The superoxide anion (O2•-) can also be dismutated into
oxygen (O2) and hydrogen peroxide (H2O2) by the antioxidant superoxide dismutase
(SOD). Once formed, H2O2 can be used in the inflammatory process or form a hydroxyl
radical (OH•) (Kehrer & Klotz, 2015). The hydroxyl radical is highly reactive, and the
cell avoids formation by detoxifying H2O2 via the antioxidant enzymes catalase and
glutathione peroxidase (West & Marnett, 2006). generation of ROS in cells exist in
equilibrium with a wide variety of antioxidant defenses.
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The antioxidant defenses include the enzymatic scavenger’s superoxide dismutase
(SOD), catalase, glutathione peroxidase and peroxiredoxins (Halliwell, 2011). There are
also non-enzymatic scavengers including vitamins C and E, glutathione (GSH), lipoic
acid, carotenoids and iron chelators (Halliwell, 2011). Normal ROS production is
important and essential for the regulation of normal physiological functions, including,
cell cycle progression and proliferation, differentiation, migration, and cell death
(Covarrubias, Hernandez-Garcia, Schnabel, Salas-Vidal, & Castro-Obregon, 2008).
Equally, ROS play a role in the immune system and in maintenance in redox balance
(Zhang et al., 2016). Lastly, ROS have been implicated in the activation of various
cellular signaling pathways and transcription factors (Zhang et al., 2016). If this control
tightly ROS, antioxidant system becomes dysregulated, oxidative stress results.
Halliwell (2011) defined oxidative stress as “a serious imbalance between the
generation of ROS and antioxidant defenses in favor of ROS, causing excessive oxidative
damage”. Oxidative stress or excess levels of cellular ROS can cause fragmentation of
amino acids in proteins, alteration of DNA bases, and lipid peroxidation to membranes
and organelles such as the mitochondria (Halliwell, 2011). Equally, oxidative stress has
been implicated in the development of pathologies, (Trachootham, Alexandre, & Huang,
2009), neurodegeneration (Andersen, 2004; Shukla, Mishra, & Pant, 2011),
atherosclerosis, diabetes (Paravicini & Touyz, 2006), aging (Haigis & Yankner, 2010),
and the promotion of tumor metastasis through gene activation (Ishikawa et al., 2008).
Relevant to the current study, is the effect that ROS have on the activation of apoptotic
signaling pathways.
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Apoptosis
Apoptosis is a specific distinct form of cell death, that occurs normally during
development and aging and as a homeostatic mechanism to maintain cell populations in
tissues. There are a wide variety of both physiological and pathological stimuli that can
trigger apoptosis, and not all cells will necessarily die at the same rate or as a result of the
same stimuli. For example, chemotherapy drugs or radiation treatment may damage
DNA in some cells leading to apoptosis via the p53-dependent pathway, where other cells
do not share the same fate (Yang, Niepel, Mitchison, & Sorger, 2010).
Although, it is not the focus of this dissertation study, it is worth noting that an
alternative to apoptosis is necrosis, the degradative process that occurs after cell death,
which some do not consider necrosis to be a viable form of cell death. However, there is
some overlap in the apoptotic/necrotic pathways, with the distinction depending on the
nature of the cell death signal, tissue type, developmental stage of the tissue, and the
physiologic milieu (Fiers, Beyaert, Declercq, & Vandenabeele, 1999; Zeiss, 2003).
Apoptosis can be triggered via two main pathways, the extrinsic and intrinsic
pathways, and in some instances the two pathways can influence one another (Igney &
Krammer, 2002). There is an additional pathway that involves T-cell mediated
cytotoxicity and perforin-granzyme-dependent killing of the cell (Kaspar et al., 2001). As
an overview of apoptosis, regardless of the pathway signaled (extrinsic, intrinsic, T-cell),
they all converge on the same terminal which is initiated by the cleavage of caspase-3.
Caspase-3 cleavage results in DNA fragmentation, degradation of cytoskeletal/nuclear
proteins, cross linking of proteins, formation of apoptotic bodies, expression of ligands
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for phagocytic cell receptors and then the uptake of the degraded parts by phagocytic
cells (Elmore, 2007).
The extrinsic apoptotic pathway involves transmembrane receptor-mediated
interactions, specifically the tumor necrosis factor receptor gene family death receptors
Fas receptor or FasR (Locksley, Killeen, & Lenardo, 2001). The binding of the Fas
ligand (FasL) to FasR, initiates the extrinsic apoptotic pathway, transmitting the death
signal from the cell surface into the intracellular signaling pathway. Fas ligand is a
transmembrane protein that binds to it receptor FasR. Fas ligands are formed when they
are cleaved by matrix metalloproteinase (MMP-7) and enter circulation. Fas ligands then
binds to the FasR on the cell surface which results in the binding of the adapter protein
Fas-associated death domain (FADD) to the death domain of Fas, via its own death
domain. FADD then associates, via dimerization, with the death domain of procaspase-8
(Wajant, 2002). This forms the death-inducing signaling complex (DISC), which
activates procaspase-8 (Kischkel et al., 1995). Activated caspase-8 will trigger the
execution phase of apoptosis (Kischkel et al., 1995).
Unlike the extrinsic apoptotic pathway that is initiated by ligand/receptor
interaction, the intrinsic apoptotic pathway is triggered by non-receptor-mediated stimuli
that produces an intracellular signal that acts directly on targets directly within the cell.
The non-receptor-mediated stimuli can either act in a positive or negative fashion. A
negative stimulus is a withdrawal of factors that suppress the pathway, thereby triggering
the pathway. A positive stimulus increases the apoptotic pathway, an example being free
radical production, which is relevant to the current study. Regardless of the nonreceptor-mediated stimuli (positive or negative) the result are changes in the inner
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mitochondrial membrane: opening of the mitochondrial permeability pore, loss of
transmembrane potential and release of two groups of normally sequestered pro-apoptotic
proteins from the intermembrane space to the cytosol (Saelens et al., 2004).
The first group of pro-apoptotic proteins that are released from the intermembrane
space via non-receptor-mediated stimuli are cytochrome c, Smac/DIABLO, and the
serine protease HtrA2/Omi (Du, Fang, Li, Y., Li, L., & Wang, 2000; Garrido et al.,
2006). The second group of pro-apoptotic proteins are apoptosis-inducing factor,
endonuclease G and CAD, which are released later than the first group of pro-apoptotic
proteins, after the cell has committed to die. The above mentioned apoptotic
mitochondrial events (i.e., the mitochondrial release of the pro-apoptotic proteins) are
controlled and regulated by Bcl-2 family of proteins and the tumor suppressor p53
regulation of Bcl-2, with the mechanisms not being entirely understood (Cory & Adams,
2002; Schuler & Green, 2001). The Bcl-2 family of proteins is quite large, containing 25
genes that have been identified in the Bcl-2 family. The Bcl-2 proteins govern
mitochondrial permeability and determine if the cell will commit to apoptosis or abort
(Cory & Adams, 2002).
The last apoptotic pathway to briefly discuss is the T-cell mediated and involves
the cytotoxic T lymphocytes (CTLs). Upon binding to the target cell, the CTLs secrete
the transmembrane pore-forming molecule perforin, which then releases its cytoplasmic
granules (granzyme A and granzyme B) through the pore into the target cell (Pardo et al.,
2004; Trapani & Smyth, 2002). Once inside, granzyme A and B act as proteases, which
end up activating procaspase-10, directly activating caspase-3 and signaling the induction
of the execution phase of apoptosis (Sakahira, Enari, & Nagata, 1998).
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All of the pathways (extrinsic, intrinsic, T-cell), once signaled, end with
triggering of the execution pathway, which is the final apoptotic pathway. In the
execution pathway, the execution caspases are activated, which activate cytoplasmic
endonucleases that begin the process of nuclear and cytoskeletal protein degradation,
nuclear material breakdown, cytoskeletal reorganization, chromatin condensation, and
disintegration of the cell into apoptotic bodies (Sakahira et al., 1998; Slee, Adrain, &
Martin, 2001). The main execution caspases (or sometimes referred to as effector
caspases) are caspase-3, caspase-6, and caspase-7, which cleave various substrates such
as poly (ADP-ribose) polymerase (PARP), alpha fodrin, NuMA, and others, which cause
the morphological changes described above (Slee et al., 2001).
Of all the execution caspases, caspase-3 is considered to be imperative for
apoptosis to occur. When there is a disruption in mitochondrial function (loss of
transmembrane potential, permeability transition and release of cytochrome c), as with
Dox therapy, the result is activation of apoptosis-activating factor 1 (AIF) and caspase -9,
leading to the processing of pro-caspase-3 (Kluck et al., 1997; Li et al., 1997; Pan,
O’Rourke, & Dixit, 1998; Reed, 1997; Zou, Henzel, Liu, Lutschg, & Wang, 1997).
Worth noting is that in caspase-9 knockout mice, caspase-3 fails to activate in the
absence of caspase-9, giving evidence that caspase-9 is a critical upstream activator of
caspase-3 (Cheng et al., 1997). Once caspase-3 is activated, downstream death substrates
are cleaved, including poly (ADP-ribose) polymerase (PARP) (Janicke, Ng, Sprengart, &
Porter, 1998). Caspase-3 can also amplify the upstream death cascade, increasing
cytochrome c release by cleaving Bcl-2 converting it from an anti-apoptotic to a proapoptotic protein (Cheng et al., 1997). In closing, apoptosis is a fundamental and
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complex biological process that enables an organism to kill and remove unwanted cells
during animal development, normal homeostasis and disease (Jacobson, Weil, & Raff,
1997; Thompson, 1995).
Reactive Oxygen Species and Apoptosis
As stated in the previous section, ROS are small molecules that are short-lived
and highly reactive (Halliwell, 2011). They can be oxygen derived like superoxide anion
(O2•-) and the hydroxyl radical (OH•), or non-radical molecules like hydrogen peroxide
(H2O2). As stated earlier, apoptosis is a tightly regulated and highly conserved process of
cell death during which a cell undergoes self-destruction (Kerr, Wyllie, & Currie, 1972).
It is also worth mentioning that apoptosis is an essential process that multicellular
organisms use to eliminates damaged cells, neutralize cells with DNA damage, and
protect against carcinogenesis (Fulda, Gorman, Hori, & Samali, 2010; Pallepati &
Averill-Bates, 2012).
Normal, low dose ROS production has been linked to a cell survival response, via
the ROS activation of the tumor suppressor protein p53 (Carafoli & Lehninger, 1971).
p53, a key protein that regulates the cellular stress response, either inducing cell cycle
arrest for cell repair, or if damage is beyond repair, triggering cell death via apoptosis
(Guerrero-Hernandez, Gallegos-Gomez, Sanchez-Vazquez, & Lopez-Mendez, 2014). At
rest, p53 is maintained at low cellular levels and rises during cell stress (GuerreroHernandez et al., 2014). As p53 levels rise during elevated cellular stress and if the
cellular damage is too severe, p53 can regulate apoptosis transcriptionally by
downregulating pro-survival proteins and upregulating pro-apoptotic proteins (GuerreroHernandez et al., 2014). The activation of the pro-apoptotic proteins can also induce the

21
activation of both the intrinsic apoptotic pathway (i.e., changes to the mitochondrial
membrane) and the extrinsic apoptotic pathway (i.e., death receptor activation).
Reactive oxygen species stimulation of the intrinsic apoptotic pathway results in
the formation of the permeability transition pore, and produces mitochondrial outer
membrane permeabilization, resulting in the mitochondria-to-cytosol translocation of
cytochrome c, AIF, or Smac/DIABLO, that trigger the caspase cascade that results in cell
death (Redza-Dutordoir & Averill-Bates, 2016). ROS can trigger the intrinsic pathway
via a number of mechanisms include directly oxidizing mitochondrial proteins, inducing
lipid peroxidation, and damaging mitochondrial DNA (mtDNA) (Redza-Dutordoir &
Averill-Bates, 2016). The mtDNA damage can results in decreased transcription of
proteins essential in the electron transport chains. The decrease in protein transcription
disrupts respiratory chain function, which further increases ROS generation. This leads
to a disruption in mitochondrial membrane potential and impaired ATP synthesis; all of
which will lead to apoptosis (Orrenius, Gogvadze, & Zhivotovsky, 2015). Equally, ROS,
particularly H2O2, can oxidize protein components of the mitochondrial permeability
transition pore (MPTP), which will cause its formation of a pore in the mitochondrial
membrane. The formation of the pore causes mitochondrial membrane
hyperpolarization, mitochondrial translocation of Bax and Bad, cytochrome c release, and
the formation of the executioner caspase-3, 6, and 7 (Nie et al., 2008).
There is a reported link between the ROS production and the extrinsic apoptotic
pathway. More specifically there seems to be a link between ROS production and TNF-a
activation, although this relationship is not completely understood. TNF-a is an
important regulator of the signaling network that promote either cell-survival or cell
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death by apoptosis (Mahmood & Shukla, 2010). ROS are important in regulation of the
TNF-R1 signaling pathway, and at high doses, ROS can trigger the TNF-R1 pathway to
drive cell death (Mahmood & Shukla, 2010). The extrinsic apoptotic death receptor
Fas/FasL pathway can also be activated by the ROS H2O2 (Pallepati & Averill-Bates,
2011). Pallepati and Averill-Bates, (2011) found that H2O2 caused up-regulation of FasL,
and FADD translocation to the plasma membrane and caspase-8 activation in the HeLa
cell line. Equally in endothelial cells, human leukemia cells, and intestinal epithelial
cells, H2O2 has been shown to increase mRNA levels of FasL and Fas and direct
activation of caspase-8 and caspase-3 (Denning et al., 2002; Suhara et al., 1998; Zhuang,
Demirs, & Kochevar, 2000). Lastly, not well understood is the capacity for ROS to
activate Fas and TNF-a which causes lipid raft formation, recruitment and activation of
Nox. Activation of the Nox family of transmembrane proteins are an important source of
ROS, and this increase in Nox-mediated ROS can feedback and further stimulate the
death receptors Fas and TNF-a, furthering Nox family activation and ROS production
(Zhang et al., 2007).
In closing, ROS at lower doses is important for proper cell survival responses,
where they can induce cell cycle arrest to promote DNA repair and survival. However, at
higher doses ROS activate the death process such as apoptosis. At these higher doses,
ROS can directly activate the intrinsic mitochondrial apoptotic pathway through
disrupting permeability of the mitochondrial membrane and through the extrinsic death
receptor apoptotic pathway by activating certain death receptors. Both ROS activated
apoptotic pathways, intrinsic and extrinsic, lead to the activation of the execution
pathway and cell death. Doxorubicin, through the process of redox cycling, creates a
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large quantity of ROS, and will increase the signaling of the intrinsic and extrinsic
apoptotic pathways, increasing the rate of cell death in all cells where doxorubicin
undergoes redox cycling.
Doxorubicin and Redox Cycling
Oxidative stress is a widely recognized mechanism of Dox-induced toxicity
(Wang et al., 2004). The development of oxidative stress with Dox treatment is driven by
two mechanisms, increased levels of ROS following Dox treatment and the
downregulation of antioxidants enzymes following Dox administration. The first
mechanism, increased ROS levels, may result from different mechanisms including 1)
decreased cellular antioxidant defenses, 2) disruption of the mitochondrial electron
transport chain with subsequent electron leakage, and 3) the ability of Dox to undergo
redox cycling and produce ROS (Zhao et al., 2010). Dox redox cycling leading to ROS
production is the most widely recognized mechanism by which oxidative stress increases
with Dox administration.
Redox cycling typically involves the reduction of a quinone molecule to form a
semiquinone radical species (Hopkins, 2016) and occurs in the cytochrome P450 enzyme
system and the mitochondrial electron transport chain. The creation of ROS with Dox
administration occurs when the semiquinone radical donates one of its electrons to
molecular oxygen. This donation reduces molecular oxygen to superoxide anion radical,
and the semiquinone radical is oxidized back to the original quinone molecule. This oneelectron reduction and oxidation cycle will continue and persist in the production of
superoxide anion radicals and secondary reactive species such as hydrogen peroxide,
hydroxyl radical, and peroxynitrite (Hopkins, 2016). Excessive ROS production can lead
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to significant cellular damage. Doxorubicin is a quinone compound and has been
proposed to undergo redox cycling, specifically in complex I of the mitochondrial
electron transport chain. During this process Dox may go through redox activation to a
semiquinone intermediate (Dox-) which generates superoxide radical upon the oneelectron reduction of O2 (Dox- + O2 ® Dox + O2-) (Zhu et al., 2016). Early research
from Davies and Doroshow (1986) demonstrated that the quinone moiety of
anthracyclines (doxorubicin) is reduced by one electron at complex I of the mitochondrial
electron transport chain. This results in the one-electron transfer to molecular oxygen to
form superoxide anion, hydroxyl radical, and hydrogen peroxide (Davies & Doroshow,
1986).
Doxorubucin has a strong capacity to trigger apoptosis, autophagy, and
morphology in skeletal muscle. In mice Dox administration resulted in a trend towards a
reduction in body weight in overall body weight and a significant increase in caspase-3,
caspase-9 and calpain activity (Mitchell, Merkel, & Quadrilatero, 2015). Equally, Dox
administration has been shown to elevate Bax, caspase-3 activity, and apoptotic DNA
fragmentation in aged mice skeletal muscle and C57BL/6 mice increasing apoptosis (Sin
et al., 2016; Yu et al., 2014). In cardiac tissue one of the mechanisms that leads to
myocardial toxicity and heart failure following Dox administration is ROS-triggering of
apoptosis (Childs, Phaneuf, Dirks, Phillips, & Leeuwenburgh, 2002; Singal et al., 2000;
Takemura & Fujiwara, 2007).
Although not completely understood, Dox administration may produce ROS
from a different mechanism. It is well understood that a molecular target of Dox is
topoisomerase IIa, which is found in proliferating cells and required for DNA replication
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(Zhu et al., 2016). However, this would not be relevant for cell that are not actively
proliferating, such as skeletal muscle cells or cardiomyocytes. Doxorubicin has also been
shown to target topoisomerase IIb, which is present in the mitochondria of all quiescent
cells (Vejpongsa & Yeh, 2014). It has been suggested when topoisomerase IIb is target
by Dox, resulting in DNA double strand breaks, defective mitochondrial biogenesis, and
increased ROS accumulation (Zhang et al., 2016). Although not completely understood,
the theory is, Dox inhibition of topoisomerase IIb may cause p53 activation via the
mitochondrial DNA damage response, repression of PPARg, PGC1a, PGC1b, leading to
mitochondrial dysfunction, increased electron leakage, superoxide formation, and
subsequent further activation of p53 (Sahin & DePinho, 2012). Regardless of the
mechanism, whether direct ROS production through redox cycling, or increased
topoisomerase IIb leading to ROS production, Dox administration leads to increased
mitochondrial superoxide production, and damage to tissue.
Creatine
Creatine monohydrate (Cr) is one of the most widely used supplements ingested
in an attempt to improve high intensity athletic performance. A large amount of research
has been done on Cr supplementation in efforts to delineate its sport-specific effects. It
has been hypothesized that Cr can act through a number of pathways and appears to be
most effective in short-bout, high-intensity physical activities. However, over the past
decade Cr used for therapeutic and chemo preventive purposes has received increasing
attention (Gualano et al., 2009). Research has showed that Cr supplementation is
beneficial in a large number of muscular, neurological, and cardiovascular diseases.
Sharov et al. (1987) demonstrated that in the presence of exogenous phosphocreatine, a
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rat heart that had been made ischemic for 35 minutes regained almost all heart function,
phosphocreatine content, and 61% of adenosine triphosphate content, whereas only 33%
recovery of heart function was observed in control. Three days of subcutaneous creatine
injections significantly reduced the rate of hypoxic seizures in 5-to-30-day-old rabbit
pups (Holtzman et al., 1999). Creatine supplement in the diets of Sprague Dawley rats
was significantly protective against malonate and 3-nitropropionic acid induced
neurotoxicity (Matthews et al., 1999). In Duchenne muscular dystrophy, orally
administered creatine monohydrate given to 9-year-old patients improved muscle
performance (Felber et al., 2000). Mazzini et al. (2001) demonstrated that creatine
supplementation significantly increased maximal isometric power in 10 different muscle
groups, in 28 patients with definite Amyotrophic Lateral Scelerosis. Stout et al. (2001)
supplemented a single patient with myasthenia gravis, 5 grams of Cr and 3 times per
week resistance exercise for 15 weeks. Stout et al. (2001) found that after creatine
supplementation and training body weight, fat free mass, upper body strength, lower
body strength and peak strength increased, without any negative effects on blood
chemistry. Creatine supplementation has been investigated in four transgenic mouse
model of Huntington’s disease, resulting in a 19% improvement in survival, delayed
onset of weight loss, slowed the development of motor symptoms, of brain atrophy, and
of atrophy of striatal neurons, lessened the formation of intranuclear inclusions, and
delayed the onset of diabetes (Wyss & Schulze, 2002). Tarnopolsky et al. (2004)
investigated oral Cr supplementation in seven patients with mitochondrial cytopathies
and found that Cr supplementation increased high intensity anaerobic and aerobic
performance. Tarnopolsky (2007) showed that Cr supplementation (5-10 g/day for 5
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days) all indices of muscle strength in 102 patients with neuromuscular disease. Lastly
Bender et al. (2007) investigated the effect of oral Cr supplementation on aging in 162
C57BI/6J and showed that supplementation increased median life span by 9%, improved
performance on neurobehavioral tests, reduced ROS, lowered accumulation of “aging
pigment” lipofuscin, upregulated genes implicated in neuronal growth, neuroprotection
and learning.
Creatine Metabolism
Creatine, or N-aminoiminomethyl-N-methylglycine, is an endogenously formed
amino acid that is taken up in diets containing fresh meat or fish. Biosynthesis of
creatine takes place in the liver and begins with the transfer of the amindino group of
arginine (synthesized in the kidneys) to glycine to yield L-ornithine and guanidinoacetic
acid, catalyzed by L-arginine:glycine amindinotransferase. The enzyme S-adenosyl-Lmethionine:N-guanidinoacetate methyltransferase then methylates the amidino group on
guanidinoacetic acid and forms creatine. Worth noting and still largely accepted, is that
creatine biosysnthesis first occurs in the kidneys with the formation of guanidinoacetate,
which is then transported through the blood to the liver where guanidinoacetate is
methylated to form creatine (Wyss & Kaddurah-Daouk, 2000). Regardless of the route,
creatine is then transported out of the liver, into the bloodstream, transported into the
tissue via the sarcolemma bound creatine transporter (Murphy et al., 2001) and stored in
the tissue (brain, brown adipose tissue, intestine, seminal vesicles fluid, endothelial cells,
and marcrophages) with the about 95% stored in skeletal muscle (Cooper, Naclerio,
Allgrove, & Jimenez, 2012). Once in skeletal muscle, Cr undergoes what is referred to as
the phosphocreatine (PCr) ‘shuttle’ system. The PCr shuttle system occurs in the
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mitochondria, where a high-energy phosphate is transferred from ATP formed in
oxidative phosphorylation, to the guanidine group on Cr, via the enzyme creatine kinase
mitochondria (CKmito). Phosphocreatine then diffuses out of the mitochondria into the
cytoplasm, where the creatine kinase cytosolic isoform catalyzes the reversible transfer of
the N-phosphoryl group from PCr to ADP to regenerate ATP. The ATP is then localized
to areas of need, and the Cr returns to the interior of the mitochondria (Wyss &
Kaddurah-Daouk, 2000). A constant fraction of the body creatine (1.1%) and PCr (2.6%)
are spontaneously and nonenzymatically converted to creatinine, with this reaction being
both pH and temperature dependent (Wyss & Kaddurah-Daouk, 2000). Creatinine will
then diffuse out of the cell, into the blood, and is excreted by the kidneys into the urine.
The converted creatinine then has to be replaced by Cr from the diet or from de novo
biosynthesis (Walker, 1979).
Creatine and Apoptosis
As described in the section above, apoptosis is a morphologically distinct and
important mode of ‘programmed’ cell death that occurs in mammalian cells. As stated
earlier, creatine supplementation can benefit a large number of muscular, neurological,
and cardiovascular diseases. One such mechanism may be creatine’s ability to modulate
apoptosis.
Rahimi, Mirzaei, Rahmani-Nia, and Salehi (2015) examined the effects of
creatine monohydrate supplementation on apoptotic markers and found that creatine
monohydrate supplementation prevented exercise induced apoptosis, as measured by
decreases in p53 concentration. It is well known that p53 plays a significant role in
regulating apoptosis by affecting the expression of apoptotic peptidase activating factor-1
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and by altering mitochondrial membrane potential (Haldar, Negrini, Monne, Sabbioni, &
Croce, 1994; Moll & Zaika, 2001). Rahimi (2011) suggested that the increase in
oxidative stress with aerobic exercise signal p53, which in turn triggered the p53
dependent apoptotic pathway to preserve genomic intensity and cellular homeostasis.
Although not directly measured, Rahimi et al. (2015) suggest that Cr may act as an
antioxidant, scavenging ROS. This then reduces the ROS-induced signaling of p53,
which was one of the findings of the study, reduced serum p53 concentration with Cr
supplementation. Sheikholeslami-Vatani and Faraji (2018) equally found that creatine
supplementation reduced apoptotic markers with exercise, reducing caspases (-3 and -9),
p53, and Bax when compared to placebo.
Sheikholeslami-Vatani and Faraji (2018) suggest that although not directly
measured, the reduction in the apoptotic markers may have been due to the ability for Cr
supplementation to reduce ROS production which reduced the signaling of the apoptotic
caspases (-3 and -9) and p53. Lastly, in exercise-induced apoptosis, Cr supplementation
reduced lipid peroxidation and glutathione peroxidase activity, and attenuated oxidative
DNA damage, with the suggested mechanisms being the potential ROS scavenging
capabilities (Basta, Skarpan’ska-Steinborn, & Pilaczyn’ska-Szczes’niak, 2006; Mirzaei,
Rahmani-Nia, Salehi, & Rahimi, 2013; Rahimi, 2011). Although not completed in
skeletal muscle, Zhu et al. (2004) showed that in focal cerebral ischemia, Cr
supplementation either directly or indirectly inhibited cytochrome c release and
downstream caspase-3 activation. Equally, Cr supplementation has been shown to reduce
caspase-3/7 activation in HL-1 cardiomyocytes (Santacruz et al., 2015). In summary, Cr
supplementation can reduce markers of apoptosis in a variety of conditions. Although the
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mechanisms are not elucidated, it is postulate that Cr acts an antioxidant, scavenging free
radicals, and reducing their quantity which ultimately reduces apoptosis.
Creatine as an Antioxidant
Creatine is the most widely used supplement advocated as an ergogenic aid
(Kraemer & Volek, 1999). The literature claims creatine supplementation increases lean
body mass, skeletal muscle strength, muscle power, and endurance (Dangott, Schultz, &
Mozdziak, 2000; Demant & Rhodes, 1999; Ingwall, 1976; Jones, Atter, & Georg, 1999;
Reid, Stokic, Koch, Khawli, & Leis, 1994). Recently, it has been suggested that creatine
could possess an antioxidant effect.
As mentioned, creatine is a downstream product of the amino acids glycine and
arginine. Arginine is a substrate in the formation of the free radical nitric oxide which is
involved in modulating metabolism, contractility of smooth and skeletal muscle, and
skeletal muscle glucose uptake (Lawler & Powers, 1998; Reid, 2001). It has been
demonstrated that amino acids such as histidine, methionine, and cysteine are susceptible
to free radical oxidation, and it is possible, that due to the amino acid makeup of creatine,
it may be susceptible to free radical oxidation as well. In fact, Vergnani et al. (2000)
showed a protective role of arginine against oxidative stress in endothelial cells. Equally,
Wu and Meininger (2000), indicated that arginine may be able to quench free radicals
such as superoxide anions (O2-). Matthews et al. (1998) first proposed that creatine
supplementation provides direct or indirect antioxidant protection against metabolic
damage in a Huntington’s disease mouse model. Lawler, Barnes, Wu, Song, and
Demaree (2002) showed that creatine has the ability to act as a direct antioxidant, capable
of removing 3 charged free radical and ROS, superoxide anions (O2-), peroxynitrite
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(OONO-), and 2,2’-azino-bis (3-ethylbenzothiaxoline-6-sulfonic acid) (ABTS+).
Important to note Lawler et al. (2002) observed that it was creatine, not creatine
phosphate, that was capable of scavenging charged radicals and the study was conducted
in an acellular setting.
Sestili et al. (2006) expounded on Lawler’s findings and investigated the
antioxidant effects of creatine on three mammalian cell lines and found Cr preloading to
be mildly but significantly cytoprotective in a dose related manner. In a follow up study,
Sestili et al. (2007) using HPLC, in an attempt to understand whether the cytoprotective
effects of Cr depend on antioxidant or an energy-related mechanism, found that tissues
accumulated free Cr at different levels, and that protection occurred only when free Cr
levels reached a certain threshold. The aforementioned study identified that the cells
(U937, HUVEC, and C2C12) pretreated with Cr and treated with H2O2 formed an
oxidation product with a molecular weight of 136amu and 150amu, with these structures
still needing to be better defined by means of infrared spectroscopy and mass-mass
spectrometry (Sestili et al., 2007). In a separate study, Sestili et al. (2009) showed that Cr
pre-treatment significantly protected mitochondrial DNA from oxidative damage, with
respect to H2O2-treated, Cr unsupplemented samples, and again, that the protective
effects were Cr dose dependent.
Doxorubicin has been shown to act as both an alkylating and an oxidizing agent,
damaging RNA (Fimognari, Sestili, Lenzi, Cantelli-Forti, & Hrelia, 2009). Cr
supplementation was able to reduce the RNA damage in Jurkat T-leukemia cells
incubated in H2O2 and Dox (Fimognari et al., 2009). Lastly, Cr supplementation
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significantly and dose-dependently attenuated the cytotoxic impact of H2O2 to
differentiating C2C12 myoblasts (Sestili et al., 2009).
In closing, it is well established that Cr supplementation can improve athletic
performance (Earnest, Snell, Rodriguez, Almada, & Mitchell, 1995). More recently,
research has demonstrated that Cr supplementation may beneficial in a large number of
muscular, neurological, and cardiovascular diseases (Bender et al., 2007; Felber et al.,
2000; Gordon et al., 1995; Holtzman et al., 1999; Matthews et al., 1999; Mazzini et al.,
2001; Neubauer et al., 1999; Sharov et al., 1987; Stout et al., 2001; Tarnopolsky et al.,
2004; Tarnopolsky, 2007; Vorgerd et al., 2000; Wyss & Schulze, 2002). Free Cr, not Cr
bound to a phosphate, can reduce apoptosis in various types Dox treated cells, possible
through its proposed antioxidant capacity. Overall, Cr supplementation is well tolerated
in humans, with the most common side effect being diarrhea and bloating. Equally, Cr
supplementation is easy to ingest, whether mixed in a liquid or taken as a pill and can be
taken with or without food. In light of the aforementioned, Cr supplementation may be
valuable nutraceutical treatment to reduce Dox-induced muscle fatigue that affects so
many cancer patients receiving Dox treatment.
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CHAPTER III
METHODOLOGY
Experimental Design
The current study examined the effects of a nutritional intervention, using two
types of creatine feeding interventions: 2% creatine feeding for four weeks (C1) and 4%
creatine feeding for one week followed by 2% creatine feeding for three more weeks
(C2). Equally, the study examined a drug effect, with rats receiving either a 15 mg/kg
injection of Dox or an equivalent sterile saline injection (Sal). Lastly, animals were
sacrificed either 1-day post injection or 3-days post injection. Western blotting technique
measured the apoptotic markers, cleaved poly ADP ribose polymerase (PARP), cleaved
caspase-3, and caspase-3 in the fast, type II extensor digitorum longus (EDL), the slow,
type I soleus (SOL) and the diaphragm (DIA). Upon sacrifice, tissues were harvested,
flash frozen in liquid nitrogen, and stored at -80°C for biochemical analysis.
Subjects
All protocols used for the study were approved by the University of Northern
Colorado Institutional Animal Care and Use Committee and followed the Animal
Welfare Act guidelines. Male Sprague Dawley rats (120 total animals; 60 animals x 1 day
and 60 animals x 3 day) were purchased from Envigo and housed at the University of
Northern Colorado Research Facility. All animals were housed individually in a
temperature-controlled facility with a 12-hour light/12-hour dark cycle. Animals were
provided their nutritional intervention and water ad libitum.
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At 10 weeks of age, the animals were assigned to one of two, four-week creatine
feeding interventions or control feeding referred to below (See Table 1.). The first
feeding protocol (creatine feeding protocol 1 or C1) attempted to duplicate human dosing
of creatine, which is typically, 10 grams per day. Creatine feeding protocol 1 (C1)
consisted of a rodent chow supplemented with 2% creatine and was feed ad libitum to the
rodents for 4 weeks. The second feeding protocol (creatine feeding protocol 2 or C2)
attempted to duplicate the human equivalent of a loading phase, which is taking 5 grams
of Cr, 4 times per day, for 7 days, then to a maintenance dose of 10 grams a day for the
duration of the supplement period. Creatine feeding protocol 2 (C2) consisted of a rodent
chow supplemented with 4% creatine for one week, followed by rodent chow
supplemented with 2% creatine for three weeks (creatine feeding protocol 2, C2).
Animals assigned to the control group were fed standard rodent chow (Teklad Global)
which is 16.4% protein, 4% fat, 48.5% carbohydrate, and 3.3% fiber, made
predominantly from ground wheat, ground corn, and wheat middlings, for four weeks.
At the end of four-week nutritional intervention, the animals were randomly
assigned to receive either an intraperitoneal bolus 15 mg/kg Dox injection or an
equivalent sterile saline injection (Sal). The final volume of the Doxorubicin injection
was calculated by first multiplying the animals body mass by 15mg/kg, then dividing by
the 2mg/ml Doxorubicin concentration. Following injections, the animals were assigned
to be sacrificed either 1-day post injection or 3-days post injection, and continued diet.
Animals were anesthetized with sodium pentobarbital (50 mg/kg). After the
rodent was completely anesthetized (i.e., no response with a tail pinch) the left soleus
(SOL), left extensor digitorum longus (EDL), and diaphragm (DIA) were removed,
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trimmed, weighed, flash frozen in liquid nitrogen, and stored at -800C for biochemical
analysis.
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Table 1
Experimental design for treatments.
Group
Diet

Drug

Sacrifice Time

Con-Sal

4 wks Con Diet

Sal

1 day (n=10), 3 day (n=10)

Con-Dox

4 wks Con Diet

Dox

1 day (n=10), 3 day (n=10)

C1-Sal

4 wks 2% Cr Diet

Sal

1 day (n=10), 3 day (n=10)

C1-Dox

4 wks 2% Cr Diet

Dox

1 day (n=10), 3 day (n=10)

C2-Sal

1 wk 4% Cr Diet - 3 wks 2% Cr Diet

Sal

1 day (n=10), 3 day (n=10)

C2-Dox

1 wk 4% Cr Diet - wks 2% Cr Diet

Dox

1 day (n=10), 3 day (n=10)

Note. Con-Sal = control saline, 1 day n=10, 3 day n=10; Con-Dox = control doxorubicin, 1 day n=10, 3 day n=10; C1-Sal = creatine 1
saline, 1 day n=10, 3 day n=10; C1-Dox, creatine 1 doxorubicin, 1 day n=10, 3 day n=10; C2-Sal, creatine 2 saline, 1 day n=10, 3 day
n=10; C2-Dox, creatine 2 doxorubicin, 1 day n=10, 3 day n=10.
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Biochemical Analyses
Homogenate Preparation
The SOL, EDL and DIA were homogenized in a cocktail of
radioimmunoprecipitation (RIPA) buffer at a 1:10 weight:volume ratio and 10 µl protease
enzyme inhibitor (Santa Cruz Biotechnology). The tissue samples (between 0.7-1.0
grams) were manually homogenized using a Cole-Parmer PTFE tissue grinder (ColeParmer: Vernon Hills, IL), sonicated using 10 x 1 second bursts (Fischer Scientific, Sonic
Dismembrator, Model 100), and then transferred to a 2 ml eppendorf tube. The
homogenate was centrifuged for 10 minutes at 10,000 g, the pellet discarded, and the
supernatant transferred to a new 2 ml Eppendorf. A Bradford Assay was performed to
assess total protein concentration using a Genesys 20 photo spectrometer
(ThermoSpectronic: Rochester, NY) at 595 nanometers. Radioimmunoprecipitation assay
buffer (RIPA) and Laemmli Sample Buffer (Sigma-Aldrich) was pipetted into each
sample to standardize the concentration of each sample.
Western Blotting
Western blot analysis was conducted on the, SOL, EDL, and DIA for the presence
of cleaved PARP (24 kilodalton), caspase-3 (32 kilodalton), and cleaved caspase-3 (17
kilodalton), and used the 35.8 kilodalton, glyceraldehyde 3-phosphate dehydrogenase
(GAPDH) as the loading control. Prepared samples were boiled in water for 2 minutes,
chilled for 5 minutes on ice, with 15 µl loaded onto 4 - 20% Tris-Glycine (Invitrogen)
precast gels, along with 10µl SeeBlue protein standard (Thermo Fisher Scientific) and 10
µl of MagicMark XP western protein standard (Thermo Fisher Scientific). Gels were run
at a constant 125V at 4 mA in an Xcell II blot module (ThermoFisher Scientific) until
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tracking dye reaches bottom of the gel. Once the protein migration was complete, the
proteins were transferred onto a polyvinylidene fluoride (PVDF) membrane at 25 volts
and100 mA for 90 minutes. Membranes were blocked using 10 ml WesternBreeze TM
Superblocker Solution (ThermoFisher Scientific) for 30 minutes, washed twice in water
for 5 minutes and then incubated overnight at room temperature in 10 mL of primary
antibody solution. Membranes were then washed four times in 10 mL of WesternBreeze
Wash Solution (ThermoFisher Scientific) and incubated for 1 hour in the species-specific
secondary antibody conjugated with horseradish peroxidase (HRP). Membranes were
then washed 4 more times with WesternBreeze Wash Solution and prepared for protein
band detection.
Protein band detection involved incubating the membranes in
Enhancedchemiluminescence (ThermoFisher Scientific, ECL) solution containing
peroxide buffer and luminol substrate, mixed in a 2 mL microcentrifuge tube
(concentration 1:1) and poured onto the center of the opened C-Digit imager (Li-Cor:
Lincoln, NE). Membranes were placed on top of the substrate face down for 5 minutes.
A cellophane sheet was then placed on top of the membrane, the lid closed, and the CDigit imager captured the image. Optical density of the protein bands was quantified
using Image J (NIH: Bethesda, MD). The ratio of cleaved PARP was quantified and this
value was divided by the optical density of GAPDH for the final optical density for
cleaved PARP, with the same process completed for caspase-3 and cleaved caspase-3.
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Table 2
Characteristics of antibodies used for Western blotting.
Antibody name
Dilution ratio
Species specificity

Source

Supplier

Catalog No.

GAPDH

1:1000

Rabbit

Mouse mAB

Santa Cruz Bio

Sc-32233

Caspase-3

1:200

Human

Mouse mAB

Santa Cruz Bio

Sc-5603

PARP-1

1:200

Human

Mouse mAB

Santa Cruz Bio

Sc-8007

M-IgGk BP-HRP
1:1000
Anti-mouse
Santa Cruz Bio
Sc-516102
Note. GAPDH = glyceraldehyde-3-phosphate dehydrogenase, PARP-1 = poly (ADP-ribose) polymerase-1, M-IgGk BP-HRP = mouse
IgG kappa binding protein conjugated to Horseradish Peroxidase, mAB = monoclonal antibody
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Creatine Assay
Creatine and phosphocreatine levels were analyzed in the SOL, EDL, and DIA at
both the 1-day and 3-days post injection time points using the commercially available
creatine assay kit (Abcam). Skeletal muscle samples (0.7-1.0 g) were homogenized in
radioimmunoprecipitation assay buffer (RIPA buffer), centrifuged for 10 minutes at
10,000 x g, then the supernatant transferred to a clean tube and the pellet discarded. The
reagents were then prepared using the materials supplied by the Creatine Assay Kit. Prior
to beginning the equipment was equilibrated and the reagents brought to room
temperature and all standards, controls, and samples duplicate. The creatine standard
wells were filled with 25 µl of the creatine standard, and 25 µl of the reaction mix. The
sample wells were filled with 8 µl of tissue supernatant, 17 µl of creatine assay buffer,
and 25 µl of reaction mix. The wells were mixed for 2 minutes and incubated in the dark
at 37°C for 60 minutes. Measurement of the wells were done on a microplate reader at
570 nm and expressed as the molar concentration of creatine per whole tissue.
Statistical Analysis
Data was presented as means ± standard error (mean±SEM). A two-way (diet x
drug) analysis of variance (ANOVA) was used at each time point to determine main diet
effect, drug effect, diet x drug, of the dependent variables (apoptotic markers: cleaved
PARP, caspase-3, cleaved caspase-3, and creatine concentration). When ANOVA
significant main effects and/or interaction were observed, and a Tukey’s post hoc testing
was performed to identify where the differences existed. Significance was set at the
a=0.05 level.
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CHAPTER IV
RESULTS
The purpose of this study was to determine the effects of two separate creatine
feeding, and acute Dox administration on apoptosis in skeletal muscle. This study
investigated the expression of cleaved PARP, caspase-3, and cleaved caspase-3 at two
separate time points following a bolus Dox injection. Equally, the concentration of total
Cr was measured in EDL, SOL, and DIA. This chapter presents the findings of the study.
General Observations
Table 3 presents the animal characteristics at the time of injection and at the 1-day
sacrifice time point. At the time of injection, there were no main effects observed in
body mass between groups, p>0.05. At the time of sacrifice, a drug effect was observed
with Dox animals exhibiting significantly lower body mass, F (1, 54) = 6.91, p<0.05. In
the EDL, there was a significant drug effect, with Dox animals having significantly lower
EDL mass, F (1, 50) = 4.24, p<0.05. In the SOL there was a significant drug effect, F (1,
54) = 5.759 and diet x drug interaction, F (2, 54) = 5.12, p<0.05, with Dox animals
having significantly lower SOL mass. Post hoc tests revealed SOL mass to be
significantly lower in the Con-Dox than Con-Sal. In the DIA, no significant main effects
were observed and no interactions were detected, p>0.05.
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Table 3
1-day animal characteristics.
Con-Sal

Con-Dox

C1-Sal

C1-Dox

C2-Sal

C2-Dox

Injection Mass (g)

390 ± 7

394 ± 10

400 ± 5

395 ± 9

387 ± 9

380 ± 14

Sacrifice Mass (g) ‡

388 ± 7

374 ± 9

397 ± 5

377 ± 9

386 ± 9

361 ± 13

EDL Mass (mg) ‡

172 ± 12

143 ± 5

166 ± 8

140 ± 18

154 ± 12

148 ± 6

SOL Mass (mg) ‡+

148 ± 5

134 ± 4 *

147 ± 4

147 ± 3

144 ± 5

143 ± 6

DIA Mass (mg)

261 ± 29

261 ± 21

271 ± 18

249 ± 24

232 ± 21

266 ± 14

Note. Con-Sal = control saline, n=10; Con-Dox = control doxorubicin, n=10; C1-Sal = creatine 1 saline, n=10; C1-Dox, creatine 1
doxorubicin, n=10; C2-Sal, creatine 2 saline, n=10; C2-Dox, creatine 2 doxorubicin, n=10. Values are means ± SEM.
‡
= signficant drug effect (p<0.05)
+
= significant interaction (p<0.05)
*
= significantly different than Con-Sal
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Biochemical Analyses
Western Blotting
Expression of the apoptic proteins, cleaved PARP, caspase 3, and cleaved caspase
3, were measured in the SOL, EDL, and DIA homogenates at the 1 and 3 day time points
to evaluate the influence of creatine monohydrate and Dox on their expression. Forty six
µg of protein from the 1 day and 3 day, SOL, EDL, and DIA homogenates were added to
4-20% Tris-glycine precast gels and run through SDS-PAGE. Cleaved PARP, caspase-3,
and cleaved caspase-3 levels were assessed by enhanced chemiluminescence and are
expressed relative to GAPDH as a loading control. No signficiant GAPDH main effects
or interactions (p>0.05) were observed, suggesting that the drug and diet treatments did
not affect the loading control.
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One-day extensor digitorum longus apoptotic protein levels. In the EDL,
cleaved PARP levels were higher with the administration of Dox, F (1, 52) = 28.12,
p<0.05 (Figure 4A). Post hoc tests revealed that Con-Dox, C1-Dox, C2-Sal, and C2-Dox
expressed significantly higher levels of cleaved PARP than C1-Sal. Post hoc tests also
revealed that C2-Dox expressed significantly higher levels of cleaved PARP than ConSal (Figure 4A). A 2-way ANOVA revealed a significant diet effect, with creatine groups
exhibiting lower levels of caspase-3, F (2, 53) = 4.142, p<0.05 (Figure 4B). No
significant main effects or interaction was detected for cleaved caspase-3 (Figure 4C).
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Figure 4. 1-day EDL apoptotic protein levels, (A) cleaved PARP, (B) caspase-3, (C)
cleaved caspase-3.
EDL = extensor digitorum longus, kDa = kilodalton, OD = optical density, Con-Sal =
control saline, n=10; Con-Dox = control doxorubicin, n=10; C1-Sal = creatine 1 saline,
n=10; C1-Dox = creatine 1 doxorubicin, n=10; C2-Sal = creatine 2 saline, n=10; C2-Dox
= creatine 2 doxorubicin, n=10; Values are mean ± SEM.
(A) significant drug and diet effect (p<0.05)
(B) significant diet effect (p<0.05)
* = significantly different from C1-Sal
+ = significantly different from Con-Sal
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One-day soleus apoptotic protein levels. For cleaved PARP, a significant drug
effect was observed, with Dox groups exhibiting higher levels of cleaved PARP, F (1,
50) = 6.30, p<0.05 (Figure 5A). A diet effect was observed, with Cr groups expressing
higher levels of cleaved PARP, F (2, 20) = 5.41, p<0.05. No significant interaction was
detected. Post hoc tests also showed that Con-Sal, C1-Sal, C1-Dox, and C2-Sal expressed
significantly lower levels of cleaved PARP than C2-Dox (Figure 5A). No significant
main effects were observed and no interaction was detected for caspase-3 (Figure 5B).
Cleaved caspase-3 levels were lower with diet, F (2, 52) = 3.43, p<0.05 (Figure 5C), and
a drug effect was not observed.
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Figure 5. 1-day SOL apoptotic protein levels, (A) cleaved PARP, (B) caspase-3, (C)
cleaved caspase-3.
SOL = soleus, kDa = kilodalton, OD = optical density, Con-Sal = control saline, n=10;
Con-Dox = control doxorubicin, n=10; C1-Sal = creatine 1 saline, n=10; C1-Dox =
creatine 1 doxorubicin, n=10; C2-Sal = creatine 2 saline, n=10; C2-Dox = creatine 2
doxorubicin, n=10. Values are mean ± SEM.
(A) significant drug ffect (p<0.05)
(C) significant diet effect (p<0.05)
* = significantly different from C2-Dox
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One-day diaphragm apoptotic protein levels. In the DIA, a significant diet
effect was observed, with Cr groups exhibiting lower levels of cleaved caspase 3, F (2,
52) = 5.01, p<0.05 (Figure 6C). No main effects or interaction observed for cleaved
PARP and caspase-3 (Figures 6A and 6B).
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Figure 6. 1-day DIA apoptotic protein levels, (A) cleaved PARP, (B) caspase-3, (C)
cleaved caspase-3.
DIA = diaphragm, kDa = kilodalton, OD = optical density, Con-Sal = control saline,
n=10; Con-Dox = control doxorubicin, n=10; C1-Sal = creatine 1 saline, n=10; C1-Dox =
creatine 1 doxorubicin, n=10; C2-Sal = creatine 2 saline, n=10; C2-Dox = creatine 2
doxorubicin, n=10. Values are mean ± SEM.
(C) significant diet effect (p<0.05)
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Table 4 presents the animal characteristics at the 3 day sacrifice time point. At the time
of injection there were no significant difference in body mass between groups, p>0.05.
At the time of sacrifice, a main effect was observed in animal body mass, p<0.05. A drug
effect was observed with Dox animals exhibiting significantly lower body mass, F (1, 54)
= 11.34, p<0.05.
There was a main effect in EDL, SOL, and DIA mass, p<0.05. In the EDL, there
was a drug effect, with Dox animals exhibiting significantly lower tissue mass, F (1, 51)
= 11.72, p<0.05. Post hoc testing revealed EDL mass to be significantly lower in the C1Dox than Con-Sal. In the SOL, there was a drug effect, with Dox animals exhibiting
significantly lower tissue mass, F (1, 51) = 4.39, p<0.05. Lastly, in the DIA there was a
significant drug effect, with Dox animals exhibiting significantly higher tissue mass, F
(1, 51) = 4.38, p<0.05.
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Table 4
3-day animal characteristics.
Con-Sal

Con-Dox

C1-Sal

C1-Dox

C2-Sal

C2-Dox

Injection Mass (g)

386 ± 13

381 ± 4

373 ± 5

387 ± 10

375 ± 6

392 ± 6

Sacrifice Mass (g) ‡

387 ± 13

351 ± 9

374 ± 5

353 ± 13

378 ± 6

352 ± 8

EDL Mass (mg) ‡

160 ± 7

142 ± 4

153 ± 7

127 ± 8 *

154 ± 6

134 ± 11

SOL Mass (mg) ‡

158 ± 9

134 ± 3

137 ± 8

137 ± 5

153 ± 7

141 ± 3

DIA Mass (mg) ‡

229 ± 21

285 ± 43

243 ± 32

299 ± 23

245 ± 16

277 ± 14

Note. Con-Sal = control saline, n=10; Con-Dox = control doxorubicin, n=10; C1-Sal = creatine 1 saline, n=10; C1-Dox, creatine 1
doxorubicin, n=9; C2-Sal, creatine 2 saline, n=10; C2-Dox, creatine 2 doxorubicin, n=10. Values are means ± SEM.
Significant drug effect in Sacrifice Mass (p<0.05).
‡ = signficant drug effect (p<0.05)
*
= significantly different than Con-Sal
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Three-day extensor digitorum longus apoptotic protein levels. No main
effects or interaction was observed for cleaved PARP and caspase-3 (Figures 7A and 7B).
A 2-way ANOVA revealed a significant diet effect, with Cr groups exhibiting higher
levels of cleaved capase-3, F (2, 49) = 17.96, p<0.05 (Figure 7C). Cleaved caspase-3
levels were higher in the Dox groups, F (1, 49) = 0.1880, p<0.05 (Figure 7C). Lastly, an
interaction was observed, with the highest cleaved caspase-3 levels observed in the C1Dox group, F (2, 49) = 7.230, p<0.05 (Figure 7C). Post hoc tests revealed that C1-Sal,
C1-Dox, and C2-Sal produced significantly higher levels of cleaved caspase-3 than ConSal. Equally, post hoc tests exposed C1-Dox and C2-Sal expressed significantly higher
levels of cleaved caspase-3 than Con-Dox. Lastly, post hoc tests showed C2-Dox
expressed significantly lower levels of cleaved caspase-3 than C1-Dox (Figure 7C).
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Figure 7. 3-day EDL apoptotic protein levels, (A) cleaved PARP, (B) caspase-3, (C)
cleaved caspase-3.
EDL = extensor digitorum longus, kDa = kilodalton, OD = optical density, Con-Sal =
control saline, n=10; Con-Dox = control doxorubicin, n=10; C1-Sal = creatine 1 saline,
n=10; C1-Dox = creatine 1 doxorubicin, n=10; C2-Sal = creatine 2 saline, n=10; C2-Dox
= creatine 2 doxorubicin, n=10. Values are mean ± SEM.
(C) significant drug and diet effect (p<0.05)
(C) significant interaction (p<0.05)
*
= significantly different from Con-Sal
†
= significantly different from Con-Dox
‡
= significantly different from C1-Dox
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Three-day soleus apoptotic protein levels. No main effects or interaction was
observed for cleaved PARP (Figure 8A). A 2-way ANOVA revealed a significant drug
effect, with Dox groups exhibiting lower levels of capase-3, F (1, 52) = 4.776, p<0.05
(Figure 8B). There were no main effects or interaction observed for cleaved caspase-3
(Figure 8C).
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Figure 8. 3-day SOL apoptotic protein levels, (A) cleaved PARP, (B) caspase-3, (C)
cleaved caspase-3.
(A) cleaved PARP, (B) caspase-3, (C) cleaved caspase-3; SOL = soleus, kDa =
kilodalton, OD = optical density, Con-Sal = control saline, n=10; Con-Dox = control
doxorubicin, n=10; C1-Sal = creatine 1 saline, n=10; C1-Dox = creatine 1 doxorubicin,
n=10; C2-Sal = creatine 2 saline, n=10; C2-Dox = creatine 2 doxorubicin, n=10. Values
are mean ± SEM.
(B) significant drug effect (p<0.05)
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Three-day diaphragm apoptotic protein levels. A 2-way ANOVA revealed a
significant drug effect, with Dox groups exhibiting lower levels of cleaved PARP F (1,
54) = 11.24, p<0.05 (Figure 9A). Post hoc tests revealed that Con-Dox expressed
significantly lower levels of cleaved PARP than Con-Sal (Figure 9A). No significant
main effects or interaction was detected for caspase-3 (Figure 9B) and cleaved caspase-3
(Figure 9C).
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Figure 9. 3-day DIA apoptotic protein levels, (A) cleaved PARP, (B) caspase-3, (C)
cleaved caspase-3.
DIA = diaphragm, kDa = kilodalton, OD = optical density, Con-Sal = control saline,
n=10; Con-Dox = control doxorubicin, n=10; C1-Sal = creatine 1 saline, n=10; C1-Dox =
creatine 1 doxorubicin, n=10; C2-Sal = creatine 2 saline, n=10; C2-Dox = creatine 2
doxorubicin, n=10. Values are mean ± SEM.
(A) significant drug effect (p<0.05)
*
= significantly different from Con-Sal
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Creatine Assay
Creatine levels were measured in the SOL, EDL, and DIA at the 1 and 3-day time
points to evaluate the effects of Cr feeding and Dox administration on the concentration
of creatine monohydrate in skeletal muscle. Eight µL of the supernatant from the 1-day
and 3-day, SOL, EDL, and DIA homogenates were added to 17 uL of creatine assay
buffer, in a 96 well plate. Twenty-five µL of the creatine reaction mix was then added to
each well, and was incubated at 37°C for 1 hour. The plates were then measured at 570
nm using a microplate reader. Results were expressed as molar (M) creatine
concentration per whole skeletal muscle (g).
One-day creatine concentration. In the 1-day EDL, a 2-way ANOVA revealed
no significant effects or interaction (Figure 10). In the SOL, a drug effect was observed,
with Dox groups displaying lower creatine concentrations, F (1, 50) = 8.005, p<0.05
(Figure 11). There were no significant main effects or interaction in the DIA (Figure 12).

Total EDL Creatine Concentration (M)
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Figure 10. 1-day EDL creatine concentration.
EDL = extensor digitorum longus; Con-Sal = control saline, n=10; Con-Dox = control
doxorubicin, n=10; C1-Sal = creatine 1 saline, n=10; C1-Dox = creatine 1 doxorubicin,
n=10; C2-Sal = creatine 2 saline, n=10; C2-Dox = creatine 2 doxorubicin, n=10. Values
are mean ± SEM.
No significant effects (p>0.05)
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Figure 11. 1-day SOL creatine concentration.
SOL = soleus; Con-Sal = control saline, n=10; Con-Dox = control doxorubicin, n=10;
C1-Sal = creatine 1 saline, n=10; C1-Dox = creatine 1 doxorubicin, n=10; C2-Sal =
creatine 2 saline, n=10; C2-Dox = creatine 2 doxorubicin, n=10. Values are mean ± SEM.
Significant drug effect (p<0.05).
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Figure 12. 1-day DIA creatine concentration.
DIA = diaphragm; Con-Sal = control saline, n=10; Con-Dox = control doxorubicin,
n=10; C1-Sal = creatine 1 saline, n=10; C1-Dox = creatine 1 doxorubicin, n=10; C2-Sal =
creatine 2 saline, n=10; C2-Dox = creatine 2 doxorubicin, n=10. Values are mean ± SEM.
No significant effects (p>0.05)
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Three-day creatine concentration. In the EDL, a 2-way ANOVA revealed a
significant diet effect F (2, 53) = 4.668, p<0.05; drug effect F (1, 53) = 29.71, p<0.05
(Figure 13). Post hoc test revealed that Con-Dox, C1-Sal, C1-Dox, and C2-Dox had
significantly lower Cr concentration than Con-Sal (Figure 13). Additionally, post hoc test
revealed C2-Dox had significantly lower Cr concentration than C2-Sal (Figure 13). No
significant main effects were observed and no interaction was detected in the SOL
(Figure 14) and the DIA (Figure 15).
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Figure 13. 3-day EDL creatine concentration.
EDL = extensor digitorum longus; Con-Sal = control saline, n=10; Con-Dox = control
doxorubicin, n=10; C1-Sal = creatine 1 saline, n=10; C1-Dox = creatine 1 doxorubicin,
n=10; C2-Sal = creatine 2 saline, n=10; C2-Dox = creatine 2 doxorubicin, n=10. Values
are mean ± SEM.
Significant diet effect (p<0.05)
Significant drug effect (p<0.05)
*
= significantly different than Con-Sal (p<0.05)
† = significantly different than C2-Sal (p<0.05)
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Figure 14. 3-day SOL creatine concentration.
SOL = soleus; Con-Sal = control saline, n=10; Con-Dox = control doxorubicin, n=10;
C1-Sal = creatine 1 saline, n=10; C1-Dox = creatine 1 doxorubicin, n=10; C2-Sal =
creatine 2 saline, n=10; C2-Dox = creatine 2 doxorubicin, n=10. Values are mean ± SEM.
No significant effects (p>0.05)
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Figure 15. 3-day DIA creatine concentration.
DIA = diaphragm; Con-Sal = control saline, n=10; Con-Dox = control doxorubicin,
n=10; C1-Sal = creatine 1 saline, n=10; C1-Dox = creatine 1 doxorubicin, n=10; C2-Sal =
creatine 2 saline, n=10; C2-Dox = creatine 2 doxorubicin, n=10. Values are mean ± SEM.
No significant effects (p>0.05)
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Summary
At the time of injection, at both the 1 and 3-day time points, main effects were not
observed in animal body mass. There was a significant drug effect in the sacrifice body
mass at both the 1 and 3-day time points, with Dox treated animals displaying lower body
masses. In both the 1 and 3-day EDL and SOL, there was a significant drug effect in
tissue mass with the Dox groups having lower tissue mass. Equally, the 3-day DIA
experienced a significant decrease in tissue mass. No mass differences were seen in the
1-day DIA.
Cleaved PARP levels were increased with Dox and Cr in both the 1-day EDL and
SOL and decreased in the 3-day DIA. Cleaved PARP levels were not significantly
different in the 1-day DIA or 3-day EDL or SOL. Caspase-3 levels were lower in the 1day EDL Cr groups and were higher in the 3-day SOL Dox gropus. There was not a
significant change in caspase-3 levels in the 1 or 3-day DIA, nor the 1-day SOL and 3day EDL. Cleaved caspase-3 levels were lower in both the 1-day SOL and DIA Cr
groups, but not in the 1-day EDL. Cleaved caspase-3 levels were lower in both Cr, Dox
groups and showed an interaction in the 3-day EDL, with no main effects observed in the
3-day SOL or DIA.
Total Cr concentration was lower in the 1-day SOL and 3-day EDL with Dox
administration. Total Cr concentration was overall lower in the 3-day EDL Cr groups.
There were no main effects or interaction observed in the 1-day EDL and DIA; 3-day
SOL and DIA.
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CHAPTER V
DISCUSSION AND CONCLUSIONS
This is the first study to assess two types of Cr diets and in vivo Dox treatment, at
two separate time points on apoptosis in skeletal muscle. It was hypothesized that Dox
would increase levels of the apoptotic proteins cleaved PARP, cleaved caspase-3, and
decrease levels of caspase-3 at both time points in all tissues and that Cr feeding would
attenuate these effects. The major findings are that 1) Dox did not increase cleaved
PARP and cleaved caspase-3 levels in all muscles analyzed and only affected cleaved
caspase-3 levels in one condition, 2) Cr feeding did not attenuate the effects of Dox on
these apoptotic proteins.
Doxorubicin and Creatine’s Effect
on Animal Characteristics
Dox animals had significantly lower sacrifice body masses at both time points.
Equally, when the 1 and 3-day EDL and SOL were excised and weighed, the Dox
animals had significantly lower tissue mass when compared to non-Dox treated groups.
This was the same for the 3-day DIA, but not the 1-day DIA. These findings are
supported by previous research demonstrating that Dox injections decrease muscle mass
in mice (Doroshow et al., 1985). Creatine feeding had no effect on sacrifice body or
skeletal muscle mass, which indicates Cr was not effective at reducing skeletal muscle
loss in Dox treated animals.
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Doxorubicin’s Effect on Apoptotic Proteins
Dox-induced oxidative stress is one of the most pronounced mechanisms by
which toxicity and eventual apoptosis is triggered in cells (Wang et al., 2004). The
development of oxidative stress with Dox treatment is propelled by two mechanisms,
increased levels of ROS following Dox treatment and the downregulation of antioxidant
enzymes following Dox administration. The first, increased ROS levels, may result from
different mechanisms, 1) decreased cellular antioxidant defenses, 2) disruption of the
mitochondrial electron transport chain with subsequent electron leakage, and 3) the
ability of Dox to undergo redox cycling and produce ROS (Zhao et al., 2010).
Doxorubicin redox cycling leading to ROS production is the most widely recognized
mechanism by which oxidative stress increases with Dox administration.
Reactive oxygen species, particularly H2O2, generated by Dox administration,
causes formation of a pore in the mitochondrial membrane, activation of caspase 9, and
ultimately the formation of executioner caspase-3, 6, and 7 (Kluck et al., 1997; Li et al.,
1997; Nie et al., 2008; Pan et al., 1998; Reed, 1997; Zou et al., 1997). Once caspase-3 is
activated, downstream death substrates are cleaved, including poly (ADP-ribose)
polymerase (PARP) (Janicke et al., 1998).
In the current study, rats were administered a 15 mg/kg bolus interaperitoneal
injection of Dox and sacrificed 1-day or 3-day post-injection. Doxorubicin
administration only affected cleaved caspase-3 levels in 3-day EDL, caspase-3 levels in
the 3-day SOL, and cleaved PARP in the 1-day EDL and SOL, and 3-day DIA.
Doxorubicin administration had no other significant effect on these particular apoptotic
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proteins in any other condition. These results agree with the original hypothesis that Dox
administration will increase levels of cleaved PARP, cleaved caspase-3, and decrease
levels of caspase-3. The literature, clearly demonstrates that Dox administration increases
caspase-3 activation in cell culture, rodent cardiomyocytes and roden tcardiac tissue,
resulting in activation of cleaved caspase-3 and eventually cleaved PARP (Asakura et al.,
1999; Ueno et al., 2006). Doxorubicin also had a greater effect on 3-day apoptotic
proteins, than 1-day apoptotic proteins. Research has demonstrated that Dox
accumulation and effects differ depending on the tissue and on the length of time spent in
the tissue (Chenard, Fabris, & MacLean, 2012). Chenard et al. (2012) found Dox
accumulation is time dependent, which could explain why Dox administraiton had the
greatest impact on apoptotic protein levels in the 3-day tissues. Equally, Hayward et al.
(2013), examined Dox accumulation in cardiac and skeletal muslce tissue and found that
Dox accumulation is highest in cardiac tissue and accumulation differs in the EDL and
SOL. Hayward et al. (2013) postulated that the accumulation differed due to Dox’s
affinity to accumulate in the mitochondria, and tissues with higher mitochondria content
have higher levels of Dox accumulation. Interestingly, Dox effects on cleaved PARP did
not follow this rationale of a greater Dox effect on 3-day tissue as compared to 1-day
tissue. Cleaved PARP levels increased in 1-day EDL and SOL, and not on 3-day EDL or
SOL. Even more confusing is the decrease in cleaved PARP levels observed in the 3-day
DIA. Additionally, previous research has demonstrated that cleaved caspase-3 is a direct
activator of cleaved PARP, cleaving PARP and activating it (Slee et al., 2001). It would
follow then, that if Dox administration increased cleaved PARP levels, a subsequent
increase in cleaved caspase-3 and decrease in procaspase-3 would follow in that tissue.
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This was not the case, there was not an increase in cleaved PARP and cleaved caspase-3
levels and a subsequent decrease in caspase-3, in any condition.
One explanation for the seemingly uncharacteristic response of cleaved PARP to
Dox administration is the PARP-1 gene is expressed constitutively. Its activation cannot
be surmised from increased protein expression, but rather by measuring the consumption
of the substrates used in its catalytic reaction (Shah et al., 2011). According to Shah et al.
(2011), to accurately measure PARP-1 activation in vivo, assessment of the formation of
pADPr, depletion of the substrate NAD+, or formation of protons resulting in the rapid
and reversible intracellular acidification, is the the most accurate and sensitive methods.
Presently, it is possible, that the results for cleaved PARP do not agree with the research,
not because Dox administration had no effect, but rather because the laboratory technique
used (Western blot) is not sensitive enough to accurately detect the activation of PARP-1.
In summary, if research by Shah et al. (2011) is correct, and in the current study
the laboratory technique used to measure cleaved PARP was not sensitive enough and we
interpret the results with caution, then what we presently observe is Dox administration
only affected apoptotic proteins in 3-day tissue, and only affected certain apoptotic
proteins in certain tissues. Doxorubicin decreased caspase-3 leveles in the 3-day SOL,
and increased cleaved caspase-3 levels in the 3-day EDL.
Creatine’s Effect on Apoptotic Proteins
Creatine monohydrate (Cr) is perhaps one of the most widely used nutraceuticals
ingested in an attempt to improve high intensity athletic performance. A large amount of
research has been done on Cr supplementation in efforts to delineate its sport-specific
effects. It is hypothesized that Cr acts through a number of pathways and appears to be
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most effective in short-term, high-intensity physical activities. However, the past decade
has shown that the use of Cr for therapeutic purposes has received increasing attention
(Gualano et al., 2009). Creatine supplementation is beneficial in a large number of
muscular, neurological, and cardiovascular diseases (Bender et al., 2007; Felber et al.,
2000; Gordon et al., 1995; Holtzman et al., 1999; Matthews et al., 1999; Mazzini et al.,
2001; Neubauer et al., 1999; Sharov et al., 1987; Stout et al., 2001; Tarnopolsky et al.,
2004; Tarnopolsky, 2007; Vorgerd et al., 2000; Wyss & Schulze, 2002), however, less
documented are the effects of Cr on Dox-induced skeletal muscle dysfunction, and there
is a lack of research on possible mechanisms leading to improvements in Dox-induced
skeletal muscle dysfunction. One such mechanism may be creatine’s ability to modulate
apoptosis.
Rahimi et al. (2015) examined the effects of creatine monohydrate
supplementation on apoptotic markers and found that creatine monohydrate
supplementation prevented exercise induced apoptosis, as measured by decreases in p53
concentration. It is well known that p53 plays a significant role in regulating apoptosis
by affecting the expression of apoptotic peptidase activating factor-1 and by altering
mitochondrial membrane potential (Haldar et al., 1994; Moll & Zaika, 2001). Rahimi et
al. (2015) suggested that the increase in oxidative stress with aerobic exercise signals
p53, which in turn triggered the p53 dependent apoptotic pathway to preserve genomic
intensity and cellular homeostasis. Although not directly measured, Rahimi et al. (2015)
suggest that Cr may act as an antioxidant, scavenging ROS. This then reduces the ROSinduced signaling of p53, which was one of the findings of that particular study, reduced
serum p53 concentration with Cr supplementation. Sheikholeslami-Vatani and Faraji
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(2018) also found that creatine supplementation reduced apoptotic markers with exercise,
reducing caspases (-3 and -9), p53, and Bax when compared to placebo.
As with Rahimi et al. (2015), Sheikholeslami-Vatani and Faraji (2018) suggest
that although not directly measured, the reduction in the apoptotic markers may have
been due to the ability for Cr supplementation to reduce ROS production which reduced
the signaling of the apoptotic caspases (-3 and -9) and p53. Lastly, in exercise-induced
apoptosis, Cr supplementation reduced lipid peroxidation and glutathione peroxidase
activity, and attenuated oxidative DNA damage with the suggested mechanisms being the
potential ROS scavenging capabilities (Basta et al., 2006; Mirzaei et al., 2013; Rahimi,
2011). Although not examined in skeletal muscle, Zhu et al. (2004) showed that in focal
cerebral ischemia, Cr supplementation either directly or indirectly inhibited cytochrome c
release and downstream caspase-3 activation. Equally, Cr supplementation has been
shown to reduce caspase-3/7 activation in HL-1 cardiomyocytes (Santacruz et al., 2015).
In summary, Cr supplementation can reduce markers of apoptosis in a variety of
conditions. Although the mechanisms are not elucidated, it is postulate that Cr acts an
antioxidant, scavenging free radicals, and reducing their quantity which ultimately
reduces apoptosis.
In the current study, rats were fed one of two experimental diets, C1 and C2.
Creatine 1 was a 2% Cr supplemented diet for four weeks, and Creatine 2 was one week
of a 4% Cr supplemented diet, followed by three weeks of a 2% Cr supplemented diet.
Based on human studies examining Cr supplementation (Casey & Greenhaff, 2000;
Greenhaff, Bodin, Soderlund, & Hultman, 1994; Stout et al., 2001), it has been
determined that Cr supplementation has to occur for long enough to raise Cr
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concentration levels enough for Cr to exert its ergogenic effects. In light of this research,
the current study employed a Cr feeding protocol that was hoped to be long enough (four
weeks) to raise Cr levels in the skeletal muscle of the animals. Equally, the current study
implemented a loading phase, with 4% Cr feeding for a week, followed by 2% Cr feeding
for three weeks. Lastly, the C2 diet attempted to increase the amount of free Cr stores
(i.e., Cr not bound to a phosphate). Research has shown that Cr can function as an
antioxidant, decreasing the free radical load on the cell (Basta et al., 2006; Mirzaei et al.,
2013; Rahimi et al., 2015). In these studies, it is free Cr that can function as an
antioxidant, and the current study attempted to increase free Cr stores via the C2 diet.
The overall findings were that Cr feeding, had the greatest impact on 1-day
apoptotic proteins. At the 1-day time point, Cr increased cleaved PARP levels in the
EDL and SOL, decreased caspase-3 levels in the EDL, and decrease cleaved caspase-3
levels in the SOL and DIA. The only effect observed at the 3-day time point was Cr
increased cleaved caspase-3 levels in the EDL.
Cleaved PARP levels increased with Cr feeding in the EDL and SOL. A search
of the literature failed to show that Cr supplementation would have an affect on cleaved
PARP. An increase in cleaved PARP means the cell is going to be killed, via apoptosis,
and as mentioned, there is no research suggesting Cr triggers apoptosis. Specifically, the
highest levels of cleaved PARP were in the C2-Dox group (although not significantly
higher than in the Con-Dox group) and C2-Sal group had significantly higher cleaved
PARP levels than in the C1-Sal group. As described in previous sections, the current
method used to measure cleaved PARP may not be sensitive enough and may be
impacting our assessment of the effects of Cr feeding on cleaved PARP in the EDL, SOL,
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and DIA. Therefore, the current results for cleaved PARP should be interpreted with
caution.
In the 1-day EDL, Cr feeding decreased caspase-3 levels, with the highest level
observed in the C1-Dox and lowest level in the C2-Dox. A higher level of caspase-3
suggests that apoptosis is not very active, with lower levels of caspase-3 indicating that
caspase-3 is being cleaved and converted to cleaved caspase-3 which is a strong driver of
apoptosis in the cell. The highest caspase-3 values were observed in the C1-Dox
condition, suggesting that the C1 feeding may have protected the cell from Dox-induced
cleaving of caspase-3. As stated with cleaved PARP, research does not indicate that Cr
supplementation by itself, would be a stimulator of apoptosis in the cell, and possilby, in
a condition where there is an increase in free radicials, Cr supplementation may decrease
cleaved caspase-3 levels in the cell. Based on this, one would postulate that cleaved
capase-3 levels, an indicator that apoptosis is occurring in the cell, would stay the same
with Cr feeding. This was the case in the 1-day SOL and DIA, where Cr feeding
decreased cleaved caspase-3 levels. However, in the 3-day EDL, Cr feeding had the
greatest effect on cleaved caspase-3 levels.
In the 3-day EDL, cleaved caspase-3 levels were significantly higher in C1-Sal,
C1-Dox, and C2-Sal when compared to Con-Sal. Surprising is the significant increase in
cleaved caspase-3 levels in the C1-Sal and C2-Sal when compared to Con-Sal. This
suggests that Cr feeding somehow increased cleaved caspase-3 levels, and potentially
apoptosis in the cells. These results do not agree with the literature, as Cr has not been
shown to drive apoptosis, especially in tissues treated with a substance similar to Dox.
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In the 3-day EDL, cleaved caspase-3 levels were significantly higher in the C1Dox and C2-Sal groups when compared to Con-Dox. Again, this suggests that Cr
feeding increased cleaved caspase-3 levels and may indicate that Cr increases apoptosis,
which is not supported in the literature.
Lastly, there was an interaction in the 3-day EDL. Cleaved caspase-3 levels were
observed to be higher in the C1-Dox group when compared to the C2-Dox group. This
agrees with the research that shows free Cr can act as an antioxidant, scavenging free
radicals that Dox administration has been shown to increase, decreasing the triggering of
apoptosis and subsequent increase in caspase-3 activation to cleaved caspase-3 (Rahimi
et al., 2015; Sheikholeslami-Vatani & Faraji, 2018).
Overall, there are several findings in the current study that do not agree with the
hypothesis or research that demonstrate that Dox drives apoptosis in cells. Doxorubicin
administration had very little effect on apoptotic proteins, especially in the 3-day tissue,
with a drug effect only being observed in 3 conditions (cleaved PARP, 3-day DIA;
caspase-3, 3-day SOL; cleaved caspase, 3-day EDL), and the decrease in cleaved PARP
levels in the 3-day DIA do not agree with the literature. Equally, Cr feeding seemed to
increase levels of apoptotic proteins, suggesting that it may somehow drive or trigger cell
damage, which is nowhere supported in the literature. Regarding cleaved PARP, it is
likely that the Western blot technique used to detect PARP activity in the current study,
may have not been the most sensitive method to tease out the possibly subtle changes in
PARP with Cr feeding and Dox administration.
The PARP gene is expressed constitutively, meaning it is expressed at a constant
level in the cell, and measuring expression of mRNA or protein will not accurately assess
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its activation. Research has shown that the response of eukaryotic cells to DNA damage
is the catalytic activation of PARP. When activated PARP splits nicotinamide adenine
dinucleotide (NAD+) to produce ADP-ribose, nicotinamide, and a proton (Affar, Shah,
Dallaire, Castonguay, & Shah, 2002). The then activate PARP strings together the ADPribose (forms polymer of ADP-ribose or pADPr) which binds and modifies cellular
proteins (Rouleau, Patel, Hendzel, Kaufmann, & Poirier, 2010). Based on this, the most
accurate and sensitive method to detect the catalytic activation of PARP is by
demonstrating the consequences of its catalytic reaction. The catalytic reaction results in
the consumption of the substrate nicotinamide adenine dinucleotide (NAD+) and
formation of polymer of ADP-ribose (pADPr or PAR), nicotinamide, and protons.
As an alternative to the techniques used in the current study to quantify changes in
PARP levels, techniques employed by Ueno et al. (2006) may be a more appropriate
option. Ueno et al. (2006) suggests Western blotting of pADPr modified proteins, which
have a signal of 110 to 250 kDa are to be probed. The method for preparing the tissue
differs, in that urea-SDS buffer is used in place of RIPA buffer. Along with Western
blot, quantification of NAD+ levels should be used to assess PARP activation. The
lowering of NAD+ substrate levels in response to DNA damage is an accurate way to
represent the activation of PARP (Vodenicharov, Ghodgaonkar, Halappanavar, Shah, R.
G., & Shah, G. M., 2005). In closing, the PARP results in the current study may not
reveal the entire findings. The PARP results may be limited by the use of a less than
ideal laboratory technique and had the techniques described by Ueno et al. (2006) been
employed, additional drug and diet effects may had been uncovered.
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The current study demonstrated very little drug effect on cleaved caspase-3 in any
tissue, no matter the time point. The caspases are collectively a family of proteases and
are the central executioners of the apoptotic pathway. The main methods designed to
detect activation of caspases are (1) measure specific synthetic substrates designed to
contain flurogenic or chromogenic leaving groups after the aspartate residue; (2) Western
blot using an antibody specific to the active caspase; (3) Western blot caspase-specific
cleaved products (PARP, cytokeratin-18, and lamin A); (4) immunocyto-chemical
localization of an activated caspase using antibodies specific to the caspase; (5)
fluorochrome-labeled inhibitors of caspases as affinity ligands that bind to the active
center of the active caspase; and (6) colored fluorescent protein covalently linked to a
small peptide that target a caspase (Darzynkiewicz, Pozarowski, Lee, & Johnson, 2011;
Tawa, Tam, Cassady, Nicholson, & Xanthoudakis, 2001). Based on the research above,
unlike the case of cleaved PARP, the Western blot method has been shown to be an
effective method for quantifying cleaved caspase-3 expression. Another possible reason
for not seeing elevated levels of cleaved caspase-3 in Dox treated animals is that when
the EDL, SOL, and DIA are extracted, they are flash frozen in liquid nitrogen and then
stored in a -80°C freezer. This essentially freezes the cellular state of the tissue in time.
Research shows that caspase levels can vary in the cell, rising and falling, and that this
undulation can differ based on tissue and on the type of caspase (Liu et al., 2017). It is
possible that what was observed in the current study is not the actual level of apoptotsis
in the muscle, but the levels of these caspases in the moment of time we extracted the
tissue. The caspase levels could differ if we extracted the tissues earlier or later, and their
levels may not accurately represent what effect Cr and Dox have on their expression.
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Equally, muscles from the animals were not all extracted at the exact same moment, and
this could explain why the caspase expression fluctuated from tissue to tissue and had no
disernable pattern from 1-day to 3-day. Worth mentioning is the effect Dox has on other
types of muscle tissue, specifically cardiac muscle tissue.
Doxorubicin’s major adverse effect is cardiotoxicity, which is the number one
factor that limits its use, and can be fatal (Jordon, 2002; Takemura & Fujiwara, 2007).
Doxorubicin accumulation is tissue dependent, with higher rates of accumulation
observed in cardiac tissue when compared to skeletal muscle tissue (Hayward et al.,
2013). This is possible due to Dox accumulating primarily in the mitochondria and
cardiac tissue has higher amounts of mitochondria when compared to both type I and type
II skeletal muscle fibers (Hayward et al., 2013). The higher the Dox dose, the greater the
incident of cardiotoxicity (Lefrak, Pitha, Rosenheim, & Gottlieb, 1973; Hayward &
Hydock, 2007). The main effects Dox treatment produces in the heart is cardiomyopathy,
referred to as doxorubicin cardiomyopathy. Interestingly, the mechanisms of Doxcardiotoxicity differ from Dox-tumor toxicity, in that the cardiotoxicity results from
increased oxidative stress, as evident from increased reactive oxygen species and lipid
peroxidation (Singal, Deally, & Weinberg, 1987). There is significant evidence that Dox
induces apoptosis of cardiomyocytes (Wang, Ma, Markovich, Chen, & Wang, P. H.,
1998; Kotamraju, Konorev, Joseph, & Kalyanaraman, 2000). The increase in oxidative
stress increases formation of hydogren peroxide and superoxide, which activates p53induced apoptosis and ultimately Dox-cardiomyopathy (Wang et al., 1998; Kotamraju et
al., 200).
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Lastly, the animal characteristic data showed a statistically significant drug effect
in both the 1-day and 3-day EDL, SOL, and DIA tissue mass. This illustrates that the Dox
treated animals (both 1-day and 3-day) lost tissue mass, which means some form of cell
death was occurring, which means cleaved caspase-3 and cleaved PARP levels would
increase. Based on this observation, I conclude the laboratory method for measuring
PARP levels and that the tissues extraction markers a point in time, are the best
explanations to somewhat describe the drug effects results of the current study.
The diet effects results are equally hard to explain. The most confusing are: Cr
feeding increased cleaved PARP levels in the 1-day EDL and SOL, and increased cleaved
caspase-3 levels in the 3-day EDL. As stated in multiple sections, research has not
demonstrated Cr supplementation to increase cleaved PARP or cleaved caspase-3 levels
in the tissue, cell culture. Interestingly, research has showed that Cr supplementation is
beneficial in a large number of muscular, neurological, and cardiovascular diseases
(Felber et al., 2000; Holtzman et al., 1999; Matthews et al., 1999; Mazzini et al., 2001;
Sharov et al., 1987; Stout et al., 2001). Equally, the animal characteristic data showed no
significant diet effect on EDL, SOL, or DIA tissue mass at either the 1-day or 3-day time
point. Based on previous Cr research and the animal characteristic data, an explanation
for the current findings that Cr supplementation may increase apoptosis in the EDL and
SOL has remained elusive.
Doxorubicin and Creatine’s Effect on
Creatine Concentration
Creatine, or methylguanidine-acetic acid, is a naturally occurring compound
synthesized from arginine, glycine, and methionine in humans in the liver and pancreas
(Bloch & Schoenheimer, 1941; Walker, 1979). Creatine is found in meat and found

80
principally in skeletal muscle, and in its free and phosphorlayted form plays a pivotal role
in the regulation and homeostasis of skeletal muscle energy metabolism (Bessman &
Fonyo, 1966; Bessman & Geiger, 1981; Meyer, Sweeney, & Kushmerick, 1984;
Walliman, Wyss, Brdiczka, Nicolay, & Eppenberger, 1992). In an average 70 kg adult,
the total creatine pool in the body amounts to about 120 g and is continuously degraded
to creatinine, and excreted in the urine at a rate of about 2 g/day (Walker, 1979).
Creatine replishment is a combination of dietary intake and endogenous systhesis and
most of the total creatine pool is contained in skeletal muscle, with 65% in a
phosphorylated form called phosphocreatine (Casey, Constantin-Teodosiu, Howell,
Hultman, & Greenhaff, 1996a; Hunter, 1922; Walker, 1979).
Human skeletal muscle is composed of several fiber types that differ substantially
in functional and metabolic characteristics. Fiber types range from type I, slow-twitch
fiber (example, soleus and diaphragm), to the type II, fast-twitch fiber (e.g., extensor
digitorum longus). Specifically, creatine metabolism differs between fiber type, with
type II fibers utilizing phosphocreatine (thus reducing free Cr to resynthesize pCr) at
greater rates than type I fibers (Greenhaff, Nevill, & Soderlund, 1994; Soderlund,
Greenhaff, & Hultman, 1992; Tesch, Thorsson, & Fujitsuka, 1989). In rodents, total
creatine concentration of type II, fast-twitch muscle is 45% greater than that of type I,
slow-twitch muscle, and that the increase in phosphocreatine concentration after creatine
supplementation is greater in type II fibers with free creatine concentration greater in type
II fibers (Casey, Constantin-Teodosiu, Howell, Hultman, & Greenhaff, 1996b; Greenhaff,
Bodin, & Casey, 1996).
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It has been shown that the ingestion of creatine can increase the total creatine
(free creatine + phosphocreatine) levels in skeletal muscle. Harris, Soderlund, and
Hultman (1992) found that 5 g creatine taken 4-6 times/day for several consecutive days
increased the total creatine concentration of human skeletal muscle by an average of 25
mmol/kg dry mass, with 30% of which occurred in phosphorylated form as
phosphocreatine. Equally, Greenhaff et al. (1993), found that ingestion of 20-30 g Cr/day
for several days can lead to a >20% increase in human skeletal muslce total Cr content.
However, in human studies, the data illustrate that there is a large variation in creatine
uptake between individuals after creatine supplementation, from 6 – 38 mmol/kg dry
mass (Casey et al., 1996a). It has been suggested that a maintenance dose of 2 g/day
after the 20-30 g/day for several days, will maintain a high total creatine concentration in
the muscle for a period of 28 days (Hultman, Soderlund, Timmons, Cederblad, &
Greenhaff, 1996). Lastly, in humans, supplementing with dose larger than 30 g/day
shows no evidence of any potentiating effect on muslce creatine uptake (Harris et al.,
1992; Hultman et al., 1996). In fact, a consistent finding from several studies is that there
appears to be a definable upper limit to the intramuscular total creatine concentration of
160 mmol/kg dry mass, and once this limit is reached, further supplementation will only
result in increased excretion of creatine in the urine (Casey et al., 1996b; Harris et al.,
1992).
The assay used in the current study quantified total Cr concentration in the
samples. This includes free Cr (creatine not bound) and Cr bound to a phosphate. This is
a limitation, in that there is no way of determining if the drug and/or diet interventions
effected the concentrations of the unbound Cr or Cr bound to a phosphate. Presently, Cr
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concentration did not increase in the EDL, SOL, or DIA, at either time point. In fact, the
only diet effect was observed in the 3-day EDL, with there being an overall lower Cr
concentration with Cr feeding. Equally, there was a drug effect in the 3-day EDL, with
lower Cr concentrations observed in rodents administered Dox. Taken together, the diet
effect observed in the 3-day EDL could be influenced by the fact that the Cr-Dox animals
had significantly lower Cr concentrations. The decrease in Cr concentration in the CrDox animals could impact the overall observation that diet decreases Cr concentration.
The only other drug effect was observed in the 1-day SOL, with Dox administration
decreasing Cr concentration levels. There was neither a drug or diet effect observed in
the DIA at either time point. Equally, no main effects were observed in the 1-day EDL or
3-day SOL. The decrease in total Cr concentration with Dox administration is not
surprising, although, the exact mechanism(s) that may have caused this is speculative.
One potential mechanism could be a reduction in creatine transport into all three skeletal
muscles via reduced quantity of cell membrane creatine transporter.
Creatine, which is synthesized in the kidneys, must be transported into tissue
(e.g., skeletal muscle) via creatine transporter which is embedded into the plasma
membrane of the cell (Guerrero-Ontiveros & Wallimann, 1998). Creatine transporters
are found in rat cardiac, skeletal muscle (quadriceps, soleus, and gastrocnemius), kidney,
and brain (Neubauer et al., 1999). Additionally, the highest expression of the creatine
transporter is found in the heart, and skeletal muscle, specifically in the soleus (GuerreroOntiveros & Wallimann, 1998; Murphy et al., 2001). Research by Darrabie et al. (2012),
found a significant and irreversible decrease in creatine transport after an incubation with
50 – 100 nmol/l doxorubicin. Similar studies have shown Dox to decrease
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phosphocreatine (pCr) and ATP, as much as 70% (Maslov et al., 2010; Ohhara, Kanaide,
& Nakamura, 1981; Seraydarian, Artaza, & Goodman, 1977). Interestingly, kinetic
analysis showed that the decrease in creatine transport was not due to Dox-induced
increased cell death, but rather to a decrease in Cr Vmax, Km, and creatine transporter
protein content (Darrabie et al., 2012). These results indicate that Dox may alter the
affinity of the creatine transporter for Cr and/or the stability of the creatine transporter
due to potential oxidative damage of sensitive amino acids in the transporter (Darrabie et
al., 2012). In the current study the drug effect in the 1-day SOL and 3-day EDL could be
due to creatine transporter dysfunction resulting in decreased Cr transport from the blood
into the EDL and DIA. As stated previously (Murphy et al., 2001), creatine transporter
expression is higher in the SOL (when compared to the EDL and DIA) and this may have
led to higher level of Cr transport into the SOL. This could be an explanation as to the
decrease in Cr concentration observed in the EDL and not the SOL. In regards to the 1day EDL, SOL and DIA, it is possible there was not enough time for Dox to damage the
creatine transporter to a significant level to affect creatine transport and subsequent Cr
concentration in the 1, 3-day DIA, 1-day EDL, and 3-day SOL
Of most interest was the effects of Dox and Cr on Cr concentration levels in the 1day EDL, 3-day SOL, and 1, 3-day DIA. No effects were observed in these muscle
tissues. This means Cr feeding did not increase or decrease creatine concentration, nor
did Dox. Research has shown Cr concentration to differ with fiber type, with free
creatine concentration greater in type II fibers (Casey et al., 1996b; Greenhaff et al.,
1996). The DIA, which is a mixture of type I and type II fibers, had similar effects as the
type II EDL. It could be that in the above mentioned skeletal muscles there was an
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increased level of Dox-induced free radical production and free Cr was acting as an
antioxidant, scavenging free radicals in these muscles. This could have resulted in lower
amounts of free Cr in these skeletal muscles, thus decreasing total Cr concentration
observed in these muscles, and not reflecting a statistical change in Cr concentration with
Cr feeding. To further support this, cleaved PARP and cleaved caspase-3 levels did not
change with Dox treatment in the 3-day SOL, and cleaved caspase-3 levels decreased
with Dox in the 3-day EDL. This could suggest that at the 3-day time point Dox may
effect the type II EDL differently than the type I SOL, resulting in higher Dox-toxicity in
the EDL than SOL. This possibly increased activity could have lead to increased use of
free Cr as an antioxidant, resulting in the observed reduction in total Cr concentration in
the 3-day EDL. Lastly, the lack of observable increase in total Cr concentration with Cr
feeding in the EDL, SOL, and DIA in the C1-Sal, and C2-Sal groups at either time point
remains unknown.
Creatine Concentration and Apoptotic
Proteins
In the current study Dox had the greatest effect on decreasing Cr concentration in
the 1-day SOL and 3-day EDL. Subsequently, the only effect observed in the 3-day EDL
was increased cleaved caspase-3 levels with both Dox and Cr. The only effect observed
in the 3-day DIA was a decrease in cleaved PARP with Dox. Creatine feeding only
decreased Cr concentration in the 3-day EDL. In the 1-day EDL, drug and diet increased
cleaved PARP levels; diet decreased caspase-3 levels, and there was no change in cleaved
caspase-3 levels. The 1-day SOL, in which there was a drug or diet effect on Cr
concentration observed, had an increase in 1-day cleaved PARP levels with drug and diet,
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and a decrease in cleaved caspase-3 with Cr feeding. Equally, caspase-3 levels were
lower in the 3-day Sol with Dox.
In closing, this is the first report examining the effects of two types of Cr feeding
and Dox on the apoptotic marker; cleaved PARP, caspase-3, and cleaved caspase-3 in
three separate skeletal muscles, at two different time points. Both Cr feeding and Dox
administration affected Cr concentration differently depending on the time point and
tissue. Apoptotic protein levels were affected by both Cr and Dox, and levels varied
depending on the protein, tissue, and time point. Overall, Dox administration and Cr
feeding affect Cr concentration and apoptotic protein levels in the EDL, SOL, and DIA at
both the 1-day and 3-day time points.
Moving forward, the results obtained indicate that Cr has some effect on skeletal
muscle treated with Dox. The current study examined the apoptotic pathway, and
previous research our lab has examined myogenic regulatory factors, and these findings
only begin to attempt to explain how Cr may be affecting Dox-induced myotoxicity. In
response, it is important to continue investigating Cr and other nutraceutical supplements
that may help reduce the negative impacts of chemotherapy on cancer patients. It is
equally important to find alternative treatments that have low side effects and are safe to
take along side traditional cancer treatments. The current findings are encouraging, that
there are compound (such as Cr) that exist that are cheap, safe, and easy to ingest, that
may improve the quality of life for cancer patients, or possibly the quality of life for
patients being treated for other diseases. In light of this, as research to find better
treatments increase (with potentially greater unpleasant, or deadly side effects), so should
research for treatments to combat the side effects of the new treatments increase. This
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approach would ultimately lead to a better quality of life for the patient and possibly
better over treatment outcomes.
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Table 5
1-day EDL apoptotic protein levels.
Con-Sal

Con-Dox

C1-Sal

C1-Dox

C2-Sal

C2-Dox

Cleaved PARP ‡ †

0.84 ± 0.05

1.07 ± 0.08 *

0.722 ± 0.03

1.03 ± 0.03 *

1.06 ± 0.03 *+

1.24 ± 0.07 *

Caspase-3 †

0.28 ± 0.06

0.21 ± 0.02

0.22 ± 0.02

0.29 ± 0.04

0.17 ± 0.01

0.15 ± 0.01

Cleaved caspase-3

0.33 ± 0.08

0.35 ± 0.10

0.22 ± 0.05

0.38 ± 0.10

0.25 ± 0.03

0.22 ± 0.07

Note. Con-Sal = control saline, n=10; Con-Dox = control doxorubicin, n=10; C1-Sal = creatine 1 saline, n=10; C1-Dox, creatine 1
doxorubicin, n=9; C2-Sal, creatine 2 saline, n=10; C2-Dox, creatine 2 doxorubicin, n=10. Values are means ± SEM.
‡ = signficant drug effect (p<0.05)
† = significant diet effect (p<0.05)
*
= significantly different from C1-Sal
+
= significantly different from Con-Sal
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Table 6
1-day SOL apoptotic protein levels.
Con-Sal

Con-Dox

C1-Sal

C1-Dox

C2-Sal

C2-Dox

Cleaved PARP ‡

0.83 ± 0.05 *

1.12 ± 0.15

0.76 ± 0.15 *

0.67 ± 0.08 *

0.86 ± 0.06 *

1.64 ± 0.33

Caspase-3

0.19 ± 0.04

0.16 ± 0.02

0.09 ± 0.02

0.14 ± 0.02

0.12 ± 0.02

0.15 ± 0.04

Cleaved caspase-3 †

1.33 ± 0.15

1.48 ± 0.19

1.06 ± 0.19

0.90 ± 0.12

1.07 ± 0.08

1.15 ± 0.21

Note. Con-Sal = control saline, n=10; Con-Dox = control doxorubicin, n=10; C1-Sal = creatine 1 saline, n=10; C1-Dox, creatine 1
doxorubicin, n=9; C2-Sal, creatine 2 saline, n=10; C2-Dox, creatine 2 doxorubicin, n=10. Values are means ± SEM.
‡ = signficant drug effect (p<0.05)
† = significant diet effect (p<0.05)
*
= significantly different from C2-Dox
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Table 7
1-day DIA apoptotic protein levels.
Con-Sal

Con-Dox

C1-Sal

C1-Dox

C2-Sal

C2-Dox

Cleaved PARP

0.43 ± 0.04

0.50 ± 0.07

0.39 ± 0.05

0.54 ± 0.04

0.52 ± 0.04

0.45 ± 0.05

Caspase-3

0.13 ± 0.02

0.11 ± 0.02

0.09 ± 0.02

0.14 ± 0.02

0.12 ± 0.02

0.08 ± 0.01

Cleaved caspase-3 †

0.08 ± 0.01

0.07 ± 0.01

0.04 ± 0.01

0.07 ± 0.01

0.05 ± 0.01

0.04 ± 0.01

Note. Con-Sal = control saline, n=10; Con-Dox = control doxorubicin, n=10; C1-Sal = creatine 1 saline, n=10; C1-Dox, creatine 1
doxorubicin, n=9; C2-Sal, creatine 2 saline, n=10; C2-Dox, creatine 2 doxorubicin, n=10. Values are means ± SEM.
† = significant diet effect (p<0.05)
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Table 8
3-day EDL apoptotic protein levels.
Con-Sal

Con-Dox

C1-Sal

C1-Dox

C2-Sal

C2-Dox

Cleaved PARP

0.76 ± 0.05

0.70 ± 0.05

0.81 ± 0.08

0.82 ± 0.08

0.75 ± 0.07

0.63 ± 0.05

Caspase-3

1.39 ± 0.16

1.06 ± 0.13

1.07 ± 0.17

1.06 ± 0.16

1.00 ± 0.17

1.02 ± 0.19

Cleaved caspase-3 †‡

0.04 ± 0.01

0.10 ± 0.03

0.31 ± 0.03 *

0.52 ± 0.08 *+

0.37 ± 0.08 *+

0.16 ± 0.03 °

Note. Con-Sal = control saline, n=10; Con-Dox = control doxorubicin, n=10; C1-Sal = creatine 1 saline, n=10; C1-Dox, creatine 1
doxorubicin, n=9; C2-Sal, creatine 2 saline, n=10; C2-Dox, creatine 2 doxorubicin, n=10. Values are means ± SEM.
†
= significant diet effect (p<0.05)
‡=
significant drug effect (p<0.05)
Significant interaction in the EDL cleaved caspase 3 (p<0.05)
*
= significantly different from Con-Sal
+
= significantly different from Con-Dox
°
= significantly different from C1-Dox
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Table 9
3-day SOL apoptotic protein levels.
Con-Sal

Con-Dox

C1-Sal

C1-Dox

C2-Sal

C2-Dox

Cleaved PARP

0.63 ± 0.06

0.66 ± 0.03

0.70 ± 0.04

0.64 ± 0.04

0.76 ± 0.06

0.63 ± 0.05

Caspase-3 ‡

1.31 ± 0.15

0.94 ± 0.05

1.06 ± 0.06

0.92 ± 0.09

1.01 ± 0.10

0.98 ± 0.11

Cleaved caspase-3

1.13 ± 0.10

1.02 ± 0.06

1.24 ± 0.05

1.18 ± 0.09

1.34 ± 0.13

1.32 ± 0.19

Note. Con-Sal = control saline, n=10; Con-Dox = control doxorubicin, n=10; C1-Sal = creatine 1 saline, n=10; C1-Dox, creatine 1
doxorubicin, n=9; C2-Sal, creatine 2 saline, n=10; C2-Dox, creatine 2 doxorubicin, n=10. Values are means ± SEM.
‡
= significant drug effect (p<0.05)
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Table 10
3-day DIA apoptotic protein levels.
Con-Sal

Con-Dox

C1-Sal

C1-Dox

C2-Sal

C2-Dox

Cleaved PARP ‡

0.64 ± 0.07

0.38 ± 0.06 *

0.56 ± 0.03

0.51 ± 0.05

0.57 ± 0.05

0.42 ± 0.05

Caspase-3

0.29 ± 0.11

0.30 ± 0.14

0.26 ± 0.08

0.20 ± 0.07

0.10 ± 0.01

0.10 ± 0.02

Cleaved caspase-3

0.16 ± 0.03

0.09 ± 0.01

0.12 ± 0.02

0.09 ± 0.01

0.09 ± 0.02

0.11 ± 0.02

Note. Con-Sal = control saline, n=10; Con-Dox = control doxorubicin, n=10; C1-Sal = creatine 1 saline, n=10; C1-Dox, creatine 1
doxorubicin, n=9; C2-Sal, creatine 2 saline, n=10; C2-Dox, creatine 2 doxorubicin, n=10. Values are means ± SEM.
‡=
significant drug effect (p<0.05).
*
= significantly different from Con-Sal

112

Table 11
1-day creatine concentration.
Con-Sal

Con-Dox

C1-Sal

C1-Dox

C2-Sal

C2-Dox

EDL (M)

0.10 ± 0.04

0.06 ± 0.01

0.05 ± 0.03

0.06 ± 0.03

0.08 ± 0.02

0.05 ± 0.03

SOL (M) †

0.09 ± 0.01

0.07 ± 0.01

0.09 ± 0.01

0.08 ± 0.03

0.10 ± 0.02

0.06 ± 0.03

DIA (M) †

0.18 ± 0.08

0.13 ± 0.09

0.15 ± 0.04

0.15 ± 0.06

0.12 ± 0.04

0.12 ± 0.04

Note. EDL = extensor digitorum longus; SOL = soleus; DIA = diaphragm; Con-Sal = control saline, n=10; Con-Dox = control
doxorubicin, n=10; C1-Sal = creatine 1 saline, n=10; C1-Dox, creatine 1 doxorubicin, n=9; C2-Sal, creatine 2 saline, n=10; C2-Dox,
creatine 2 doxorubicin, n=10. Values are means ± SEM.
† = significant drug effect (p<0.05)
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Table 12
3-day creatine concentration.
Con-Sal

Con-Dox

C1-Sal

C1-Dox

C2-Sal

C2-Dox

EDL (µM/µg) † ‡

0.09 ± 0.02

0.05 ± 0.01 *

0.06 ± 0.01 *

0.05 ± 0.01 *

0.07 ± 0.02

0.03 ± 0.02*+

SOL (µM/µg)

0.10 ± 0.04

0.09 ± 0.009

0.09 ± 0.03

0.09 ± 0.007

0.09 ± 0.04

0.07 ± 0.04

DIA (µM/µg)

0.18 ± 0.10

0.14 ± 0.06

0.16 ± 0.07

0.18 ± 0.05

0.21 ± 0.11

0.11 ± 0.06

Note. EDL = extensor digitorum longus; SOL = soleus; DIA = diaphragm; Con-Sal = control saline, n=10; Con-Dox = control
doxorubicin, n=10; C1-Sal = creatine 1 saline, n=10; C1-Dox, creatine 1 doxorubicin, n=9; C2-Sal, creatine 2 saline, n=10; C2-Dox,
creatine 2 doxorubicin, n=10. Values are means ± SEM.
†
= significant diet effect (p<0.05).
‡
= significant drug effect (p<0.05).
*
= significantly different than Con-Sal (p<0.05).
+
= significantly different than C2-Sal (p<0.05).

